使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Align Technology first-quarter 2012 earnings call. At this time all participants are in a listen only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions).
各位女士、先生,感謝您稍候,歡迎參加 Align Technology 2012 會計年度第一季財報電話會議。此刻所有與會者皆處於僅收聽模式。正式簡報結束後將進行簡短的問答環節。(接線員指示)。
As a reminder, this conference is being recorded. It is now my pleasure to introduce Ms. Shirley Stacy of Align Technology. Ms. Stacy, you may begin
提醒各位,本次會議將被錄音。現在我很榮幸介紹 Align Technology 的 Shirley Stacy 女士。Align Technology 的 Shirley Stacy 女士。Stacy 女士,您可以開始了。
Shirley Stacy - VP, Corporate and Investor Communications
Shirley Stacy - VP, Corporate and Investor Communications
Good afternoon and thank you for joining us. I am Shirley Stacy, Vice President of Corporate and Investor Communications. Joining me today is Tom Prescott, President and CEO; and Ken Arola, our Vice President and CFO.
各位下午好,感謝您加入我們。我是 Shirley Stacy,企業與投資人溝通副總裁。今天與我一同出席的有總裁暨執行長 Tom Prescott,以及我們的副總裁兼財務長 Ken Arola。
We issued our first-quarter fiscal 2012 financial results press release today via GlobeNewswire, which is available on our website at investor.aligntech.com.
我們今天已透過 GlobeNewswire 發布 2012 會計年度第一季財務結果新聞稿,可於我們網站 investor.aligntech.com 查閱。
Today's conference call is being audio webcast and will be archived on our website for approximately 12 months. A telephone replay will be available today by approximately 5.30 PM Eastern time through 5.30 PM Eastern Time on May 1, 2012. To access the telephone replay domestic callers should dial 877-660-6853 with account number 292 followed by pound and conference number 391936 followed by pound. International callers should dial 201-612-7415 with the same account number and conference number.
今天的電話會議將以音訊網路直播,並在我們網站上存檔約 12 個月。電話重播將於今日美東時間約下午 5:30 提供,並持續至 2012 年 5 月 1 日美東時間下午 5:30。美國境內來電者欲收聽電話重播,請撥 877-660-6853,輸入帳號 292 後按井字鍵,再輸入會議號碼 391936 後按井字鍵。國際來電者請撥 201-612-7415,並使用相同的帳號與會議號碼。
As a reminder, the information that the presenters discuss today will include forward-looking statements including without limitation statements about Align's future events, product outlook and the expected financial results for the second quarter of fiscal 2012.
提醒各位,今天簡報者所討論的資訊將包含前瞻性陳述,包括但不限於關於 Align 未來事件、產品展望,以及 2012 會計年度第二季預期財務結果的陳述。
These forward-looking statements are only predictions and involve risks and uncertainties such that actual results may vary significantly. These and other results are set forth in more detail on our Form 10-K for the fiscal year ended December 31, 2011.
這些前瞻性陳述僅為預測,並涉及風險與不確定性,因此實際結果可能有重大差異。這些以及其他結果在我們截至 2011 年 12 月 31 日止會計年度的 Form 10-K 中有更詳細的說明。
These forward-looking statements reflect beliefs, estimates and predictions as of today, and Align expressly assumes no obligation to update any such forward-looking statements.
這些前瞻性陳述反映截至今日的信念、估計與預測,Align 明確表示不承擔更新任何此類前瞻性陳述的義務。
Please also note that on this conference call we will provide listeners with several financial metrics determined on a non-GAAP basis for comparisons to previous quarters. Most of these items, together with the corresponding GAAP numbers and the reconciliations of the comparable GAAP financial measures, where practical, are contained in today's financial results press release, which have been posted on our website at investor.aligntech.com under Financial Releases, and have been furnished to the SEC on Form 8-K. We encourage listeners to review these items.
另請注意,在本次電話會議中,我們將向聽眾提供若干以非 GAAP 基礎計算的財務指標,以便與前幾季比較。其中多數項目,連同相對應的 GAAP 數字以及可比 GAAP 財務衡量指標的調節表(在可行的情況下),均載於今日的財務結果新聞稿;該新聞稿已張貼於我們網站 investor.aligntech.com 的 Financial Releases(財務發布)欄位,並已以 Form 8-K 提交給美國證券交易委員會(SEC)。我們鼓勵聽眾查閱這些項目。
We have also posted a set of GAAP and non-GAAP historical financial statements, including the corresponding reconciliation, and our first-quarter conference call slides on our website at investor.aligntech.com under Quarterly Results. Please refer to these files for more detailed information.
我們也已在 investor.aligntech.com 的 Quarterly Results(季度結果)欄位張貼一組 GAAP 與非 GAAP 歷史財務報表(含相對應的調節表),以及第一季電話會議簡報投影片。如需更詳細資訊,請參閱這些檔案。
With that I would like to turn the call over to Align Technology's President and CEO, Tom Prescott. Tom?
接下來我想把電話交給 Align Technology 的總裁暨執行長 Tom Prescott。Tom?
Tom Prescott - President, CEO
Tom Prescott - President, CEO
Thanks, Shirley. Good afternoon everyone. On the call today I will provide an overview of our performance in two operating segments, Invisalign Clear Aligners, as well as Scanner and CAD/CAM services, and comment on a few highlights from each during the quarter. Ken will discuss or Q1 financial results and our outlook for Q2 in more detail. And then I will come back with a few closing comments and open the call to your questions.
謝謝你,Shirley。各位下午好。今天的電話會議中,我將概述我們兩個營運部門的表現:Invisalign 隱形矯正器,以及掃描器與 CAD/CAM 服務,並評論本季各部門的幾項重點。Ken 將更詳細說明我們第一季財務結果以及對第二季的展望。之後我會回來做幾點結語,並開放各位提問。
I am pleased to report a very strong quarter and a great start to the year. Strong Invisalign volume, particularly from North American Orthodontists, drove better-than-expected revenue, margins and EPS. And we achieved a major milestone, our first $100 million quarter in North American sales.
我很高興報告本季表現非常強勁,為今年帶來良好開局。Invisalign 出貨量強勁,尤其來自北美矯正專科醫師,帶動營收、毛利率與每股盈餘(EPS)優於預期。我們也達成一項重大里程碑:北美銷售首次單季突破 1 億美元。
In addition, our Scanner and CAD/CAM services business was up nicely this quarter. I'm very proud of our team and the great results they delivered, which reflect on their continued focus and execution of our strategic growth initiatives.
此外,我們的掃描器與 CAD/CAM 服務業務本季也有不錯的成長。我為團隊以及他們交出的優異成果感到非常自豪,這反映出他們持續專注並落實我們的策略性成長計畫。
I will start with an overview of Invisalign performance by customer channels. For our North American ortho customers total case volume for Q1 was 32,200 cases, an increase of 8% from Q4 and 20% year-over-year, driven primarily from increased utilization.
我將先從依客戶通路別的 Invisalign 表現概述開始。在北美矯正專科客戶方面,第一季總病例量為 32,200 例,較第四季增加 8%,年增 20%,主要由使用率提升所帶動。
Our Ortho customers continue to report increased confidence in using Invisalign because of the clinical improvements from Invisalign G3 and Invisalign G4, and from our ever-improving ability to create patient demand for Invisalign. These drivers are especially important in helping increase use of Invisalign for teenage patients.
我們的矯正專科客戶持續回報,因 Invisalign G3 與 Invisalign G4 的臨床改善,以及我們持續提升創造 Invisalign 病患需求的能力,使他們對使用 Invisalign 的信心提高。這些驅動因素對於提升 Invisalign 在青少年病患的使用尤其重要。
For our North American GP Dentists Q1 case volume of 33,000 was basically flat from a strong Q4, and up 17% from the same quarter last year. Year-over-year growth among GPs reflects continued expansion in our customer base, as well as utilization growth across all tiers, low, mid and high-volume GPs.
在北美一般牙醫(GP)方面,第一季病例量為 33,000 例,較強勁的第四季基本持平,較去年同期成長 17%。GP 的年增成長反映我們客戶基礎持續擴大,以及所有層級(低、中、高量)GP 的使用率成長。
Our GP customers continue to report solid patient traffic in their offices, along with increased interest in higher-value procedures, both of which are important contributors to their positive outlook. A recent dental industry survey of 200 doctors by AFG reaffirmed this view as GPs reported positive trends for practice activity, procedure volume, appointment calendars and increased patient inquiries for elective procedures.
我們的 GP 客戶持續回報其診所病患來診量穩健,且對較高價值療程的興趣增加,這兩者都是支撐其正向展望的重要因素。AFG 近期對 200 位醫師所做的牙科產業調查也再次印證此觀點:GP 回報診所活動、療程量、約診行事曆,以及病患對自費選擇性療程的詢問均呈現正向趨勢。
For our international doctors Q1 case volume of 20,000 cases increased 2% sequentially, bucking typical seasonality in Europe which tends to be down a bit in Q1 given that many practices close for extended winter holiday. Our core European countries, which make up the majority of international revenue, continued to perform well despite economic concerns. Growth this quarter was driven primarily by Italy and Spain, and we are making progress in the UK, where we are reestablishing growth.
在國際市場醫師方面,第一季病例量為 20,000 例,較前一季增加 2%,打破歐洲第一季通常因許多診所冬季長假休診而略為下滑的季節性。我們的歐洲核心國家(占國際營收的大宗)儘管面臨經濟疑慮,仍持續表現良好。本季成長主要由義大利與西班牙帶動;同時我們在英國也取得進展,正重新建立成長動能。
On a year-over-year basis international volumes increased over 23%, reflecting growth across all core European countries as well as through our Invisalign distributors. We continue to make good progress with our distribution partners in the numerous small and emerging country markets as their growth rates continue to outpace those of core Europe and North America.
以年對年來看,國際出貨量成長超過 23%,反映所有歐洲核心國家以及透過我們 Invisalign 經銷商的成長。我們與眾多小型及新興國家市場的通路夥伴持續取得良好進展,這些市場的成長率仍持續超越歐洲核心市場與北美。
Continuing this progress requires us to integrate all our strategic initiatives, particularly technology and product innovation. The prevalence of more complex cases and an ever-demanding -- an ever more demanding clinical environment outside North America increases the importance of key features in Invisalign G3 and G4 that are designed to make challenging tooth movement easier for doctors to achieve. We believe this type of product innovation should continue supporting growth in these geographies.
要延續這項進展,我們必須整合所有策略性計畫,尤其是技術與產品創新。北美以外地區更常見較複雜病例,以及日益嚴苛——更為嚴苛的臨床環境,使得 Invisalign G3 與 G4 中為協助醫師更容易達成具挑戰性牙齒移動而設計的關鍵功能更顯重要。我們相信此類產品創新應能持續支持這些地區的成長。
This continued adoption growth across our customer base really shows up in our key Invisalign metrics of utilization and new customer training. Overall, utilization rates remain strong and continue to increase, reflecting the positive effect on adoption from improved clinical features in G3 and G4.
這種在客戶基礎上的持續採用成長,清楚反映在我們 Invisalign 的關鍵指標:使用率與新客戶訓練。整體而言,使用率仍維持強勁並持續上升,反映 G3 與 G4 改善的臨床功能對採用率帶來的正面效果。
We are also on track with new doctor training, which was down slightly in Q1, as expected, as we typically offer fewer CE1 training courses during the first quarter of the year.
我們在新醫師訓練方面也按計畫進行;第一季略為下降,符合預期,因為我們通常在每年第一季提供較少的 CE1 訓練課程。
Now I would like to provide a brief update on our continued progress with G3 and G4, and the very important teenage orthodontic market as we head into the busy summer months. In October we launched Invisalign G4, our next generation of clinical and product innovation. New and improved SmartForce features in G4 helped doctors achieve even better clinical results in more difficult clinical situations, including treatment for open bite cases, which is really gaining traction with our doctors.
接下來我想簡要更新我們在 G3 與 G4 的持續進展,以及在進入繁忙夏季月份之際非常重要的青少年矯正市場。10 月我們推出 Invisalign G4,這是我們新一代的臨床與產品創新。G4 中新增且改良的 SmartForce 功能,協助醫師在更困難的臨床情境下達成更佳的臨床結果,包括開咬病例的治療;這項應用確實正快速獲得醫師採用。
G4 expands on the success of G3, which introduced new aligner and software features that make it easier to use Invisalign when treating Class II and Class III patients.
G4 延續並擴大了 G3 的成功;G3 推出了新的矯正器與軟體功能,使在治療第二類(Class II)與第三類(Class III)患者時更容易使用 Invisalign。
Customer response to G4 features has been very positive. To more fully make this point, I will share some new findings from a recent quantitative survey we did covering over 1,300 North American doctors. The findings clearly indicate that G4 is having a significant positive impact on doctor perceptions and usage of Invisalign in North America.
客戶對 G4 功能的反應非常正面。為了更充分說明這一點,我將分享我們近期針對 1,300 多位北美醫師所做的一項量化調查的新發現。調查結果清楚顯示,G4 正在對北美醫師對 Invisalign 的觀感與使用情況產生顯著的正面影響。
The objective of the survey was to help us gauge doctor awareness of G4 features and benefits, as well as the impact G4 is having on their perceptions and use of Invisalign.
本次調查的目的,是協助我們衡量醫師對 G4 功能與效益的認知程度,以及 G4 對其對 Invisalign 的觀感與使用所帶來的影響。
While we have a lot of feedback from both orthos and GPs, I will focus primarily on ortho responses, as they are more likely to use and benefit from the features designed for complex treatment. These results included awareness of G4 is high. Over 99% of preferred, premiere and elite doctors, both Ortho and GP, are aware of G4.
雖然我們從矯正專科醫師(ortho)與一般牙醫(GP)都收到了大量回饋,但我將主要聚焦在矯正專科醫師的回覆,因為他們更可能使用並受益於為複雜治療所設計的功能。結果顯示,對 G4 的認知度很高。在偏好級(preferred)、菁英級(premiere)與頂尖級(elite)醫師中,不論是矯正專科或一般牙醫,超過 99% 都知道 G4。
Doctors believe they will get better clinical outcomes because of G4, and are now more likely to use Invisalign for complex cases. Specifically 93% of the elite and premier orthos and 84% of preferred orthos believe G4 will help them achieve better clinical outcomes. And 80% of elite and premier orthos say that because of G4 they will treat more complex cases with Invisalign than they would have treated in the past.
醫師相信 G4 能帶來更好的臨床結果,因此現在更可能在複雜病例中使用 Invisalign。具體而言,93% 的頂尖級與菁英級矯正專科醫師,以及 84% 的偏好級矯正專科醫師認為,G4 將幫助他們達成更佳的臨床結果。此外,80% 的頂尖級與菁英級矯正專科醫師表示,因為有 G4,他們將用 Invisalign 治療比過去更多的複雜病例。
And, finally, these survey results indicate that the innovations in G4 are increasing doctors' clinical confidence with Invisalign and their likelihood to recommend Invisalign to patients.
最後,這些調查結果顯示,G4 的創新正在提升醫師使用 Invisalign 的臨床信心,以及其向患者推薦 Invisalign 的可能性。
There is a lot of rich detail in this research, which will inform our continuing product evolution strategy and gives us lots of confidence that our progress should continue.
這項研究包含大量豐富的細節,將為我們持續的產品演進策略提供指引,也讓我們對於進展可望持續充滿信心。
Now I will move on to the teenage orthodontics segment, which for us consists of teenagers 19 and younger using any Invisalign product. The teenage market is the largest segment of orthodontic case starts, and represents a great opportunity for us to continue taking share in existing wires and brackets case starts.
接下來我將談到青少年矯正市場區隔;對我們而言,這指的是 19 歲及以下的青少年使用任何 Invisalign 產品。青少年市場是矯正病例啟動(case starts)中最大的區隔,對我們而言是持續在既有鋼絲與托槽病例啟動中提升市占的絕佳機會。
In Q1 the total number of teenagers starting treatment with Invisalign products decreased slightly from Q4. Teenage cases grew sequentially among North American orthos, but were offset by fewer starts among North American GPs and international doctors.
第一季(Q1)使用 Invisalign 產品開始治療的青少年總數,較第四季(Q4)略有下降。北美矯正專科醫師的青少年病例按季成長,但被北美一般牙醫與國際醫師較少的啟動數所抵銷。
On a year-over-year basis teenage use of Invisalign increased 21%, and was up nicely across all customer channels, especially North American orthos, which grew 26%. This is solid progress, considering approximately 40% of teenage starts are initiated in the summer months.
以年對年來看,青少年使用 Invisalign 增加了 21%,且在所有客戶通路均有不錯的成長,尤其是北美矯正專科醫師成長 26%。考量約有 40% 的青少年病例啟動發生在夏季月份,這是相當扎實的進展。
Overall, we are seeing orthos using Invisalign on teenage patients more often. An additional piece of market research of over 400 -- 500 customers, like the previous research I described a moment ago, reaffirmed that increased utilization for teens among orthos is based on improved perceptions of Invisalign's clinical efficacy and our ability to create patient demand for Invisalign.
整體而言,我們看到矯正專科醫師更常將 Invisalign 用於青少年患者。另一項針對 400 至 500 位客戶的市場研究(與我剛才描述的前一項研究類似)再次確認,矯正專科醫師對青少年使用率的提升,係基於對 Invisalign 臨床療效觀感的改善,以及我們創造 Invisalign 患者需求的能力。
A few key takeaways from this study include the following. 55% of orthos said they increased their use of Invisalign with teenage patients in 2011. 47% of orthos cited Invisalign's improved efficacy as the primary reason why they increased their usage of Invisalign with teenage patients. 30% cited greater patient demand, prospective patients asking for Invisalign by name as the primary reason why they increased their usage with teens.
本研究的幾項重點結論如下。55% 的矯正專科醫師表示,他們在 2011 年增加了對青少年患者使用 Invisalign 的比例。47% 的矯正專科醫師指出,Invisalign 療效的提升是他們增加青少年使用量的主要原因。30% 則指出患者需求增加(潛在患者指名要求 Invisalign)是他們提高青少年使用量的主要原因。
And, finally, looking out the remainder of the year, 63% of orthos said they expect an increased usage of Invisalign among their teenage patient population.
最後,展望今年剩餘時間,63% 的矯正專科醫師表示,他們預期在其青少年患者族群中,Invisalign 的使用量將會增加。
Use of the Invisalign Teen product, which is primarily targeted at younger teens 11 to 15, and has specific features such as compliance indicators and eruption tabs to address the needs of younger patients, grew slightly sequentially and 25% year-over-year, positive indication of our continued progress.
Invisalign Teen 產品的使用量(主要鎖定 11 至 15 歲的較年輕青少年,並具備如配戴依從性指示器與萌出標籤等特定功能,以滿足較年輕患者需求)按季略增,且年對年成長 25%,這是我們持續進展的正面指標。
We are very pleased with our results within the teenager segment. It remains very competitive, and it is not easy to win share from the traditional wires and bracket suppliers that still own most of the case starts in this area. The clinical standard for excellent finishes is even higher for teenage patients than it is for adults, and doctors and parents are unwilling to make clinical trade-offs, which is both our greatest opportunity and challenge.
我們對青少年區隔的成果非常滿意。該市場競爭依然非常激烈,因為傳統鋼絲與托槽供應商仍掌握此領域大多數的病例啟動,要從其手中贏得市占並不容易。青少年患者對於「優異收尾」的臨床標準甚至高於成人,而醫師與家長不願在臨床效果上做出取捨;這既是我們最大的機會,也是最大的挑戰。
That said, we are confident we'll continue to make steady progress in increasing Invisalign's share, especially among the teenage population.
即便如此,我們有信心將持續穩健推進 Invisalign 市占的提升,尤其是在青少年族群之中。
Now let's shift to our Invisalign consumer strategy. Our goal for this important series of initiatives is to raise awareness of Invisalign and Invisalign Teen as the best options for a healthy, beautiful smile among adults, as well as teens and their parents, particularly moms. On that basis our consumer strategy supports continued share gain among the teenage segment, as well as driving long-term category expansion of orthodontics, especially among adults.
現在讓我們轉向 Invisalign 的消費者策略。這一系列重要計畫的目標,是在成人,以及青少年與其父母(特別是母親)之間,提高對 Invisalign 與 Invisalign Teen 作為健康、美麗笑容最佳選擇的認知。基於此,我們的消費者策略將支持青少年區隔持續提升市占,同時推動矯正類別的長期擴張,尤其是在成人市場。
We were on TV for much of Q1 with our ads focused on women, along with complementary radio ads in key markets, as well as online media. In Q2 we will continue to focus on the adult audience using TV, radio and print, and we will also leverage our media placement to reach moms and teams ahead of the busy summer season for ortho case starts.
第一季(Q1)我們在電視上投放了大部分時間的廣告,主打女性族群,並在重點市場搭配廣播廣告,以及線上媒體。第二季(Q2)我們將持續透過電視、廣播與平面媒體聚焦成人受眾,同時也會運用媒體投放,在矯正病例啟動旺季的夏季來臨前,觸及母親與青少年。
Earlier this month we began airing our Twins TV commercial which will run for 14 weeks through August. It will be supplemented by radio, digital and traditional PR and event marketing. On the public relations front Invisalign was featured in the April issue of InStyle, one of the most popular women's lifestyle magazines. We are also focusing PR efforts on the release of our new consumer smile survey, including media interviews with beauty and health experts.
本月稍早我們開始播出 Twins 電視廣告,將連續播出 14 週至 8 月。並將以廣播、數位媒體,以及傳統公關與活動行銷加以補強。在公關方面,Invisalign 登上了《InStyle》4 月號,這是最受歡迎的女性生活風格雜誌之一。我們也將公關重點放在發布新的消費者微笑調查,包括安排與美容與健康專家的媒體訪談。
Finally, we are gearing up for the 2012 Disney Next Big Thing Tour, sponsored by Invisalign Teen. This is our second-year working with a leader like Disney, and has been a very successful partnership for us in terms of reaching teens and their parents at a local market level. This year's tour kicks off in six cities starting in July, so the Align team is looking forward to another successful summer with Disney.
最後,我們正積極籌備由 Invisalign Teen 贊助的 2012 Disney Next Big Thing Tour。這是我們與 Disney 這樣的領導品牌合作的第二年;就於在地市場層級觸及青少年及其父母而言,這一直是非常成功的合作夥伴關係。今年的巡迴將自 7 月起在 6 個城市啟動,因此 Align 團隊期待與 Disney 再度迎來一個成功的夏季。
Generating consumer demand is important for sustained growth in North America as well as to build long-term brand equity. Increasingly, albeit on a small base, it is both strategically valuable and tactically useful to raise the level of our consumer efforts in Europe.
創造消費者需求對於北美的持續成長以及建立長期品牌資產都很重要。此外,雖然基礎仍小,但在歐洲提高我們的消費者行銷力度,正變得同時具有策略價值與戰術效用。
Over the past few years we have been laying the foundation for direct-to-consumer advertising by helping customers in key markets get ready for increased consumer demand. This quarter we launched our first TV ad in Spain focused primarily on Madrid and Barcelona, and expect to run through the end of this month. Similar to North America, the focus of our advertising is to raise awareness of Invisalign, principally among women as the best option.
過去幾年,我們一直在為直接面向消費者(DTC)的廣告奠定基礎,協助重點市場的客戶為增加的消費者需求做好準備。本季我們在西班牙推出第一支電視廣告,主要聚焦馬德里與巴塞隆納,預計播出至本月底。與北美類似,我們廣告的重點是提升對 Invisalign 的認知,主要鎖定女性族群,將其定位為最佳選擇。
Moving onto our Scanner and CAD/CAM services segment, Q1 revenues for both was $11.8 million compared with $10 million in Q4. The sequential increase was primarily driven by increased scan fees and OrthoCAD services. In addition, we recognized subscription revenue that had previously been deferred to the new iTero dual scanner software upgrade that became available in January.
接著談到我們的掃描儀與 CAD/CAM 服務業務區隔,第一季(Q1)兩者合計營收為 1,180 萬美元,較第四季(Q4)的 1,000 萬美元增加。按季成長主要由掃描費用與 OrthoCAD 服務增加所帶動。此外,我們也認列了先前遞延的訂閱收入,該收入與 1 月推出的新 iTero 雙掃描儀軟體升級相關。
The new iTero dual scanner allows multispecialty practices to utilize one iTero scanner to service all their scanning needs, including crown and bridge, implants and orthodontic treatment. Existing iTero customers who want to add the iOC orthodontic functionality can also upgrade their scanner software.
全新的 iTero 雙掃描器讓多專科診所可使用一台 iTero 掃描器滿足所有掃描需求,包括牙冠與牙橋、植體以及矯正治療。現有 iTero 客戶若希望新增 iOC 矯正功能,也可升級其掃描器軟體。
As we have come upon our one year anniversary of the Cadent acquisition next week, I'm proud of our team and the integration of business milestones we have achieved. I would like to briefly recap our progress and update you on the key areas of focus going forward.
下週我們將迎來收購 Cadent 一週年,我為我們的團隊以及我們所達成的業務整合里程碑感到自豪。我想簡要回顧我們的進展,並向各位更新未來的重點聚焦領域。
Our goal from the beginning was to continue solid execution of the Invisalign business, while managing through the Cadent acquisition and integration. As you can see from our results, the core Invisalign business remains very strong.
我們從一開始的目標,就是在管理 Cadent 的收購與整合過程中,持續穩健執行 Invisalign 業務。從我們的業績結果可以看出,Invisalign 核心業務依然非常強勁。
As we originally set up our priorities for the integration, the key objectives were, one, to drive growth of Invisalign through interoperability with Cadent scanners, and by using Cadent internal scanning system as a platform for chair-side Invisalign applications.
如同我們最初設定整合優先事項時所規劃的,關鍵目標包括:第一,透過與 Cadent 掃描器的互通性推動 Invisalign 成長,並以 Cadent 的內部掃描系統作為椅旁 Invisalign 應用的平台。
Two, to accelerate adoption of intra-oral scanning and dental practices through Align's global sales and marketing reach and our large customer base. Three, to accelerate development and delivery of unique chair-side digital tools for a range of procedures, such as real-time Invisalign case treatment planning. And, four, accelerate the key Cadent product and technology programs already underway.
第二,透過 Align 的全球銷售與行銷觸及能力以及我們龐大的客戶基礎,加速口內掃描在牙科診所的採用。第三,加速開發並交付一系列獨特的椅旁數位工具,以支援多種療程,例如即時的 Invisalign 病例治療規劃。第四,加速推進 Cadent 既有且已在進行中的關鍵產品與技術計畫。
Overall, we're executing well, and the majority of our goals and objectives are on track. In many ways we are ahead of our original key milestones. Interoperability for iTero and iOC is available in market. The Invisalign outcome simulator is in beta test mode, and is expected to launch later this year. Additional chair-side applications are in development and a whole series of scanner-enabling technology is in the pipeline.
整體而言,我們執行良好,多數目標與目的皆按計畫推進。在許多方面,我們已超前原先設定的關鍵里程碑。iTero 與 iOC 的互通性已在市場上提供。Invisalign 結果模擬器正處於 Beta 測試階段,預計將於今年稍晚推出。其他椅旁應用正在開發中,且一整系列可強化掃描器能力的技術也在研發管線中。
At the same time, this progress has not been achieved without some challenges. Over the past year we have been working to integrate the Cadent business into Align's larger global infrastructure. Unfortunately, in the course of creating a more integrated business, we have negatively impacted several important customer-facing functions like customer service, tech support and even delivery schedules in some cases.
同時,這些進展並非沒有挑戰。過去一年,我們一直致力於將 Cadent 業務整合進 Align 更大的全球基礎架構。不幸的是,在打造更整合的業務過程中,我們對幾項重要的客戶端功能造成了負面影響,例如客服、技術支援,甚至在某些情況下也影響了交付時程。
We are disappointed to have inconvenienced our customers and their patients and are committed to getting that back on track.
我們對於造成客戶及其病患的不便感到抱歉,並承諾將盡快讓相關運作回到正軌。
We continue to be very bullish about the Scanner and CAD/CAM services business, and the enormous opportunity for bringing digital technology and treatment to chair-side and helping to improve the practice of dentistry.
我們仍然非常看好掃描器與 CAD/CAM 服務業務,以及將數位技術與治療帶到椅旁、協助提升牙科臨床實務的巨大機會。
And I will now turn the call over to Ken for a review of our Q1 financial results, and I will see you in a minute or two. Ken?
接下來我將把電話會議交給 Ken,請他回顧我們第一季的財務結果,我稍後一兩分鐘後再回來。Ken?
Ken Arola - VP of Finance, CFO
Ken Arola - VP of Finance, CFO
Thanks, Tom. Before I get started, I would like to remind everyone that there are several items we excluded from our GAAP results when we report non-GAAP results. These include acquisition and integration related costs, amortization of intangible assets, and severance and benefits costs for the New Jersey consolidation.
謝謝你,Tom。在我開始之前,我想提醒各位,我們在報告非 GAAP 結果時,從 GAAP 結果中排除了幾個項目。這些包括與收購及整合相關的成本、無形資產攤銷,以及新澤西整併所產生的資遣與福利成本。
In my comments today I will not review the total dollars excluded for non-GAAP gross margin, operating expense and operating margin, and instead will refer you to our press release tables for reconciliation of GAAP to non-GAAP key financial metrics and the business outlook summary for a complete reconciliation.
在我今天的說明中,我不會逐一回顧為計算非 GAAP 毛利率、營業費用與營業利益率而排除的總金額,而是請各位參考我們新聞稿表格中 GAAP 與非 GAAP 主要財務指標的調節表,以及業務展望摘要中的完整調節。
Now let's review our first-quarter financial results beginning with revenue. Q1 net revenue was a total of $135.1 million, which consisted of Invisalign revenue of $123.3 million and Scanner CAD/CAM Services revenue of $11.8 million. This is a sequential increase of 4.8% from $128.9 million in quarter four 2011, and a year-over-year increase of 28.8% from $104.9 million in Q1 2011.
現在我們從營收開始回顧第一季財務結果。第一季淨營收合計為 1.351 億美元,其中 Invisalign 營收為 1.233 億美元,掃描器 CAD/CAM 服務營收為 1,180 萬美元。相較 2011 年第四季的 1.289 億美元,季增 4.8%;相較 2011 年第一季的 1.049 億美元,年增 28.8%。
In Q1 Invisalign revenue of $123.3 million increased 3.7% compared to Q4 revenue of $118.9 million, an increase of 17.6% compared to Q1 2011 revenue of $104.9 million. The sequential increase in Q1 revenue reflects increased North America ortho case volume, with international being up slightly and North America GPs being essentially flat from quarter four.
第一季 Invisalign 營收 1.233 億美元,較第四季的 1.189 億美元成長 3.7%;較 2011 年第一季的 1.049 億美元成長 17.6%。第一季營收的季增主要反映北美矯正病例量增加;國際市場小幅上升,而北美一般牙醫(GP)與第四季相比大致持平。
This volume growth was partially offset by lower international ASPs driven by the successful uptake of a promotion targeted towards lower-volume doctors in Europe and foreign exchange rates. On a year-over-year basis Q1 Invisalign revenue growth was driven primarily by higher volumes across all customer channels.
此一量的成長部分被較低的國際 ASP(平均銷售價格)所抵銷,該下降主要由於在歐洲針對低量醫師的促銷活動獲得成功採用,以及外匯匯率影響。以年對年來看,第一季 Invisalign 營收成長主要由各客戶通路的出貨量提升所帶動。
In Q1 Scanner and CAD/CAM services revenue of $11.8 million increased from $10 million in quarter four, and was driven by the CAD/CAM services with scanner revenue slightly up from quarter four.
第一季掃描器與 CAD/CAM 服務營收為 1,180 萬美元,高於第四季的 1,000 萬美元;成長主要由 CAD/CAM 服務帶動,而掃描器營收較第四季略有增加。
Now moving on to gross margins and operating expenses. Q1 GAAP gross margin was $100.8 million or 74.6%. This compares to $95.6 million or 74.1% in quarter four and $82.2 million or 78.4% in the same quarter last year.
接著談毛利率與營業費用。第一季 GAAP 毛利為 1.008 億美元,毛利率 74.6%。相較之下,第四季為 9,560 萬美元、毛利率 74.1%;去年同期為 8,220 萬美元、毛利率 78.4%。
Q1 GAAP gross margin for Invisalign was 79% and scanner and CAD/CAM services was 28.7%. This is compared to 78.7% and 20%, respectively, in quarter four.
第一季 Invisalign 的 GAAP 毛利率為 79%,掃描器與 CAD/CAM 服務為 28.7%。相較第四季分別為 78.7% 與 20%。
Non-GAAP gross margin for Q1 was $101.5 million or 75.1%. This compares to non-GAAP gross margin of $96.9 million or 74.9% in quarter four. There was no difference between GAAP and non-GAAP gross margin for Q1 2011.
第一季非 GAAP 毛利為 1.015 億美元,毛利率 75.1%。相較第四季非 GAAP 毛利為 9,690 萬美元、毛利率 74.9%。2011 年第一季 GAAP 與非 GAAP 毛利率之間沒有差異。
For Invisalign there was no difference between GAAP and non-GAAP gross margin for Q1 2012 or Q1 and Q4 2011. For Scanner and CAD/CAM services Q1 non-GAAP gross margin was 34.6% compared to 30% last quarter.
就 Invisalign 而言,2012 年第一季以及 2011 年第一季與第四季,GAAP 與非 GAAP 毛利率皆無差異。就掃描器與 CAD/CAM 服務而言,第一季非 GAAP 毛利率為 34.6%,高於上一季的 30%。
The sequential increase in Q1 non-GAAP gross margin primarily reflects the increased Invisalign case volume which resulted in greater absorption of manufacturing costs. In addition, the Scanner and CAD/CAM services segment also drove better-than-expected absorption of manufacturing costs.
第一季非 GAAP 毛利率的季增,主要反映 Invisalign 病例量增加,使製造成本的吸收更充分。此外,掃描器與 CAD/CAM 服務部門也帶動了優於預期的製造成本吸收。
Q1 GAAP operating expense was $72.8 million, and this compares to Q4 operating expense of $69.1 million and $61.2 million in the same quarter last year. Q1 GAAP -- Q1 non-GAAP operating expense was $71.1 million, and this compares to $66.9 million in Q4 and $59.7 million in the same quarter last year.
第一季 GAAP 營業費用為 7,280 萬美元;相較第四季為 6,910 萬美元、去年同期為 6,120 萬美元。第一季非 GAAP 營業費用為 7,110 萬美元;相較第四季為 6,690 萬美元、去年同期為 5,970 萬美元。
As expected, the sequential increase in Q1 non-GAAP operating expense was primarily driven by increased media spend after being off air for much of the fourth quarter, and as expected, annual increases in employee compensation and benefits programs.
如預期,第一季非 GAAP 營業費用的季增主要由媒體投放增加所致,因第四季多數時間未投放廣告;同時也如預期,員工薪酬與福利方案的年度調升亦推升費用。
Q1 GAAP operating income was $28 million or 20.7%, and this compares to GAAP operating income of $26.4 million or 20.5% in quarter four and $21 million or 20% in the same quarter a year ago.
第一季 GAAP 營業利益為 2,800 萬美元,營業利益率 20.7%;相較第四季 GAAP 營業利益為 2,640 萬美元、營業利益率 20.5%;去年同期為 2,100 萬美元、營業利益率 20%。
Q1 non-GAAP operating income was $30.3 million or 22.4%. This compares to $29.7 million or 23% in Q4 and $22.5 million or 21.5% in the same quarter last year.
第一季非 GAAP 營業利益為 3,030 萬美元,營業利益率 22.4%。相較第四季為 2,970 萬美元、營業利益率 23%;去年同期為 2,250 萬美元、營業利益率 21.5%。
Q1 GAAP diluted earnings per share was $0.26 compared to $0.25 in quarter four and $0.20 in the same quarter last year. Q1 non-GAAP earnings per share on a diluted basis was $0.27 compared to $0.28 in Q4 and $0.21 in Q1 of last year.
第一季 GAAP 稀釋後每股盈餘為 0.26 美元,較第四季的 0.25 美元及去年同期的 0.20 美元為高。第一季非 GAAP 稀釋後每股盈餘為 0.27 美元,較第四季的 0.28 美元及去年第一季的 0.21 美元相比。
Now moving on to the balance sheet. Cash, cash equivalents and marketable securities were $257.2 million, and this comparison $248.1 million at the end of 2011. In Q1 we generated roughly $15.4 million in cash from operations compared to $42 million in quarter four and $17.2 million in the same quarter last year.
接下來談資產負債表。現金、約當現金及有價證券為 2.572 億美元,相較於 2011 年底的 2.481 億美元。第一季我們由營運活動產生約 1,540 萬美元現金,相較第四季的 4,200 萬美元及去年同期的 1,720 萬美元。
Q1 DSOs were 63 days compared to 64 days in Q4 and 63 days in the same quarter last year. As you may recall, last quarter we announced that our Board of Directors had authorized a stock repurchase program of up to $150 million. During Q1 we repurchased approximately 100,000 shares at an average price of $24.68 per share for a total of $2.5 million. We have $139.7 million remaining under the authorization.
第一季應收帳款週轉天數(DSO)為 63 天,較第四季的 64 天及去年同期的 63 天相比。各位或許記得,上季我們宣布董事會已核准一項最高 1.5 億美元的庫藏股回購計畫。第一季我們以每股平均 24.68 美元回購約 10 萬股,總金額 250 萬美元。在該授權額度下尚餘 1.397 億美元。
Now let's turn to our business outlook for Q2 2012. As we come off a strong quarter one and enter quarter two, our Invisalign doctors in North America continue to report steady patient flow in their offices. In international the Invisalign business showed solid Q1 performance, especially in Italy and Spain, and we have begun to restage growth in the UK.
現在來看我們對 2012 年第二季的業務展望。在第一季表現強勁之後進入第二季,我們北美的 Invisalign 醫師持續回報診所病患流量穩定。在國際市場,Invisalign 業務第一季表現穩健,尤其在義大利與西班牙,我們也開始在英國重新加速成長。
For Scanner and CAD/CAM services North America had a good start for the year and we anticipate building on this in quarter two. Internationally we continue to see a more challenging environment for Scanners and CAD/CAM Services.
就掃描器與 CAD/CAM 服務而言,北美今年開局良好,我們預期第二季將在此基礎上持續成長。在國際市場,我們仍看到掃描器與 CAD/CAM 服務面臨較具挑戰的環境。
With that as a backdrop, we expect Q2 revenues to be in a range of $140.2 million to $143.7 million. Invisalign case volume is expected to be in a range of 91,300 to 93,300 cases, year-over-year an increase of 20.1% to 22.7% when compared to Q2 2011.
在此背景下,我們預期第二季營收將介於 1.402 億至 1.437 億美元。Invisalign 病例量預期介於 91,300 至 93,300 例,與 2011 年第二季相比,年增 20.1% 至 22.7%。
Let's move on to gross margin. We expect Q2 GAAP gross margin to be in a range of 73.5% to 74.2%, and we expect non-GAAP gross margin to be in a range of 73.8% to 74.5%.
接著談毛利率。我們預期第二季 GAAP 毛利率介於 73.5% 至 74.2%,非 GAAP 毛利率介於 73.8% 至 74.5%。
The expected sequential decrease in non-GAAP gross margin reflects a full quarter of depreciation associated with bringing our new facility in Juarez online, and we will be training more doctors in Q2. Remember, training revenues carry virtually no gross margin.
非 GAAP 毛利率預期的季減,反映我們位於華雷斯(Juarez)的新廠正式上線後,相關折舊費用將完整反映一整季,且我們將在第二季訓練更多醫師。請記得,訓練收入幾乎不帶來毛利。
In Q2 we expect GAAP operating expense to be in a range of $74.8 million to $76.3 million. We expect Q2 non-GAAP operating expense to be in a range of $73.5 million to $75 million. The sequential increase in non-GAAP operating expense reflects increase in TV, media spend as we get in front of the teenage summer rush, continued international investments, and our participation in a number of dental conferences including the upcoming AAO meeting.
第二季我們預期 GAAP 營業費用介於 7,480 萬至 7,630 萬美元。我們預期第二季非 GAAP 營業費用介於 7,350 萬至 7,500 萬美元。非 GAAP 營業費用的季增,反映為迎接青少年暑期旺季而增加電視與媒體投放、持續的國際投資,以及我們參與多場牙科會議(包括即將到來的 AAO 年會)。
We expect Q2 GAAP operating margin to be in a range of 20.1% to 21.1% and GAAP earnings per share to be in a range of $0.25 to $0.27. We expect Q2 non-GAAP operating margin to be in a range of 21.3% to 22.3%, and non-GAAP earnings per share to be in a range of $0.26 to $0.28.
我們預期第二季 GAAP 營業利益率介於 20.1% 至 21.1%,GAAP 每股盈餘介於 0.25 至 0.27 美元。我們預期第二季非 GAAP 營業利益率介於 21.3% 至 22.3%,非 GAAP 每股盈餘介於 0.26 至 0.28 美元。
In Q2 we expect the effective tax rate to be approximately 25%. We expect diluted shares outstanding to be approximately 83 million, and cash on hand to be in the range of $272 million to $280 million.
第二季我們預期有效稅率約為 25%。我們預期稀釋後流通股數約為 8,300 萬股,期末現金餘額介於 2.72 億至 2.80 億美元。
With that I will now turn the call back over to Tom for some closing comments.
接下來我把電話交回給 Tom,請他做一些結語。
Tom Prescott - President, CEO
Tom Prescott - President, CEO
Thanks, Ken. Well, it is a great feeling to get 2012 started off with such a strong quarter. It is also very gratifying to see our hard work pay off in the form of great results for our customers and their patients, as well as our shareholders, employees and business partners.
謝謝你,Ken。嗯,2012 年能以如此強勁的一季開局,感覺非常好。也很欣慰看到我們的努力以優異成果回饋給客戶及其病患,同時也回饋給股東、員工與業務夥伴。
While proud of these accomplishments, I am mindful of the importance of continued focus and effort and execution of our strategies and plans so that we can continue on our path to become a leader in orthodontics and digital dentistry.
在為這些成就感到自豪的同時,我也深知持續專注、努力並落實我們的策略與計畫的重要性,讓我們能持續朝成為齒顎矯正與數位牙科領導者的道路前進。
We fully intend to use this momentum as we head into a busy time of year with our major orthodontic industry tradeshow, AAO, here in a week or so, a series of other dental conferences, forums around the country, a busy training calendar both in North America and Europe. In short, it is a great time to be out with our customers.
我們完全打算在接下來一年中最忙碌的時期延續這股動能:大約一週後將舉行我們齒顎矯正產業的重要展會 AAO,還有一系列其他牙科會議、全國各地的論壇,以及北美與歐洲都排得很滿的訓練行程。簡而言之,現在正是與客戶密切互動的好時機。
In addition, we are on track to bring further new products, technology and key initiatives to the market over the summer months, and we will build our highly successful consumer marketing program. This team is focused on execution of our winning strategy, committed to delivering on these results, and passionate about bringing positive change to this industry.
此外,我們也按計畫在夏季數月推出更多新產品、技術與關鍵計畫,並將擴大我們非常成功的消費者行銷方案。這個團隊專注於執行我們的致勝策略,致力於交付這些成果,並熱衷於為這個產業帶來正向改變。
We continue to set tough goals and I look forward to sharing more of our progress towards them during our call this time next quarter. And with that I will turn it over to the operator for some questions.
我們持續設定具挑戰性的目標,我期待在下季同一時間的電話會議中,與各位分享我們朝這些目標邁進的更多進展。接下來我把電話交給接線員,開始問答。
Operator
Operator
(Operator Instructions). Brandon Couillard, Jefferies.
(接線員指示)。Brandon Couillard,Jefferies。
Brandon Couillard - Analyst
Brandon Couillard - Analyst
Thanks for taking the question. Ken or Tom, could you speak to the second-quarter revenue guidance? It appears to assume, at least from a case volume perspective, a little bit stronger sequential growth from the first quarter to the second than Then we have seen historically. Anything else underlying the strength there, whether it is international or in the US that may be stronger than usual?
謝謝讓我提問。Ken 或 Tom,能否談談第二季營收指引?看起來至少就病例量而言,該指引假設第一季到第二季的季增幅度比我們過去歷史所見略強一些。是否還有其他支撐這個強度的因素,不論是國際市場或美國市場,可能比往常更強?
Ken Arola - VP of Finance, CFO
Ken Arola - VP of Finance, CFO
You know, I guess what I would point to is that some of the comments we just made, which has to do with the clinical innovation in the products to get doctors to use the product more frequently in their practice and recommend it more frequently, that coupled with the fact that patient flow seems to be there and pretty steady in the doctors' offices is certainly contributing to that overall volume as well.
你知道,我想我會指出的是我們剛才提到的一些評論,也就是產品的臨床創新,讓醫師在其診療中更頻繁地使用產品並更常推薦;再加上醫師診所的病患流量似乎確實存在且相當穩定,這些都在推動整體量能。
And if you go over to Europe, we've certainly seen -- you know, coming off a strong fourth-quarter Europe had a very strong first quarter, even though it was only slightly up, typically they are down. And we see the UK starting to resurge there a bit as well. So I don't know, is there, Tom, anything else you want to add?
如果你把焦點轉到歐洲,我們確實看到——你知道,在歐洲第四季表現強勁之後,第一季也非常強,即使只是小幅成長;通常第一季是下滑的。我們也看到英國開始有些回升。所以我不確定,Tom,你還有什麼想補充的嗎?
Tom Prescott - President, CEO
Tom Prescott - President, CEO
I think you covered it, Ken.
我想你已經涵蓋了,Ken。
Brandon Couillard - Analyst
Brandon Couillard - Analyst
Thanks, that is helpful. And then the Cadent demand appeared to be much healthier in the first quarter then sentiment seemed when we were here back in February. How do we think about the outlook for that business going into the second quarter? And can you quantify the impact of the deferred revenue booked in the first?
謝謝,這很有幫助。另外,Cadent 的需求在第一季看起來健康得多,相較於我們二月在這裡時市場情緒所呈現的狀況。我們該如何看待該業務進入第二季的展望?以及你能否量化第一季認列的遞延收入所帶來的影響?
Ken Arola - VP of Finance, CFO
Ken Arola - VP of Finance, CFO
Yes, it was about $500,000 roughly that was -- we took -- it was purchased -- it came in as part of the purchased accounting that we did with the acquisition. And we had to deliver dual scanners to the doctors with that capability. And once we did, we had some -- about $0.5 million of revenue deferred. There is a little bit more coming in the next quarter or two as we continue to upgrade a few other systems out there in the field.
是的,大約是 50 萬美元左右——那是我們在收購時所做的購買會計處理的一部分。我們必須向醫師交付具備該功能的雙掃描器。一旦完成交付,我們就有一些——大約 50 萬美元的收入先行遞延。隨著我們持續在現場升級其他幾套系統,接下來一到兩季還會再有一些進來。
Tom Prescott - President, CEO
Tom Prescott - President, CEO
Brandon, just to follow on that. I think we are -- as I said, we are bullish about this business over the long term, and notwithstanding some softness in Europe on capital. And then secondarily we see -- we are very early in the process for this whole segment, but we see real strong interest out there among potential buyers. It doesn't mean it is going to turn out (inaudible) growing a rocket, it just means we see the opportunity to build an installed base and start to leverage that over time.
Brandon,我只是接續剛才那點。我認為我們——如我所說,我們對這項業務的長期前景持樂觀態度,儘管歐洲在資本支出方面有些疲軟。其次,我們看到——我們在這整個細分領域的進程還非常早期,但我們確實看到潛在買家有非常強烈的興趣。這不代表它會變成(聽不清)像火箭一樣成長,只是表示我們看到建立裝機基礎並隨時間開始加以槓桿運用的機會。
Brandon Couillard - Analyst
Brandon Couillard - Analyst
Great, thank you.
很好,謝謝。
Operator
Operator
Glen Santangelo, Credit Suisse.
Glen Santangelo,瑞士信貸。
Glen Santangelo - Analyst
Glen Santangelo - Analyst
Tom, could you kind of comment a little bit on ASP in terms of what you saw this quarter? I think if I go back to your comments last quarter I think you guys were expecting that the ASP would be down on a sequential basis, and yet it was obviously a little bit stronger on a sequential basis. And so I am kind of curious was it mix or was it less of the rebate program or was it something -- change with respect to FX? And then how should we think about that as we look out over the next quarter or two?
Tom,你能否就本季你們看到的ASP(平均銷售單價)稍微評論一下?我記得回到你們上季的評論,你們當時預期ASP會較前一季下滑,但實際上它顯然在季比上更強一些。所以我有點好奇,這是產品組合的因素,還是回饋(rebate)方案的影響較小,或是——外匯(FX)方面有什麼變化?另外,展望接下來一兩季,我們應該如何看待這件事?
Ken Arola - VP of Finance, CFO
Ken Arola - VP of Finance, CFO
Yes, Glen --.
是的,Glen——。
Tom Prescott - President, CEO
Tom Prescott - President, CEO
I am going to say, yes, and let Ken answer.
我先說是,然後讓Ken來回答。
Glen Santangelo - Analyst
Glen Santangelo - Analyst
Okay.
好的。
Ken Arola - VP of Finance, CFO
Ken Arola - VP of Finance, CFO
This is Ken, I will respond to that. So during the quarter here we saw a little better ASP in North America with -- we saw doctors overall increase in doing business with us -- a number of doctors, so the base of doctors. Overall we thought we would see higher levels of rebates from all doctors in general.
我是Ken,我來回應。所以在本季,我們看到北美的ASP稍微好一些——我們看到醫師整體上與我們往來的程度提高——醫師數量增加,也就是醫師基礎擴大。整體而言,我們原本以為一般來說會看到所有醫師的回饋水準更高。
So the good thing is we saw more doctors participating, but -- and starting more volume in the business, but they were lower-volume doctors this quarter as opposed to some of the higher-volume doctors, achieving higher levels of rebates. So that had a favorable impact to ASPs.
好消息是我們看到更多醫師參與——並開始帶來更多業務量——但本季參與的多是低量醫師,而不是一些高量醫師去達到更高等級的回饋。因此這對ASP帶來了有利影響。
There were other miscellaneous discounting programs in North America that were probably a little bit favorable as well. On the international side, FX came in a little bit better than we were anticipating from an ASP perspective also.
北美還有其他一些零星的折扣方案,可能也稍微偏有利。在國際市場方面,從ASP角度看,外匯(FX)表現也比我們預期稍微好一些。
And then looking at quarter two -- you know, coming into quarter one, boy, we were looking at FX rates around EUR1.28, EUR1.29 to the dollar for the euro. They seem to be a little more stable right now, I guess, at EUR1.32, EUR1.33-ish range. So we take into account where we think FX is going to go.
再看第二季——你知道,進入第一季時,天啊,我們看到的匯率大約是歐元兌美元EUR1.28、EUR1.29。目前看起來更穩定一些,我想大概在EUR1.32、EUR1.33左右的區間。所以我們會把我們認為外匯走勢可能到哪裡納入考量。
And the program I referred to as -- had an impact on ASPs in international in my prepared comments, had to do with a program we were running on a very focused basis in the basically January and February to get lower-volume doctors to utilize Invisalign more in their practice. And that was again targeted, it is not going to be necessarily repeated every quarter. It was successful, so the team is evaluating that.
我在事先準備的講稿中提到、對國際ASP有影響的那個方案,是我們在一月與二月以非常聚焦的方式推行的一個計畫,目的是讓低量醫師在其診所中更多使用Invisalign。那同樣是有針對性的,不一定會每一季都重複。它是成功的,所以團隊正在評估。
Glen Santangelo - Analyst
Glen Santangelo - Analyst
So, Ken, just to follow up. So it doesn't sound like it -- and I didn't get a chance to go back through all the different product lines in the back of the press release -- but it sounds like it wasn't so much mix, it was more that there were less rebates that you had to pay out versus what you thought.
所以,Ken,我再追問一下。聽起來不像是產品組合的問題——我也沒機會回頭把新聞稿後面所有不同產品線都看一遍——但聽起來主要不是mix,而是你們實際需要支付的回饋比你們原先想的少。
Ken Arola - VP of Finance, CFO
Ken Arola - VP of Finance, CFO
That is correct.
沒錯。
Tom Prescott - President, CEO
Tom Prescott - President, CEO
Glen, this is probably I think the largest number of docs participating we have ever had in our history, ortho and North America, GP North America as well as international. And as our customer base gets wider, it is mix in a way. It is doctors that aren't yet necessarily in Advantage yet, or aren't participating at the same level as Advantage, so on a total basis more of the case volume and the shipments came from those doctors that were low-volume customers. So that is a positive ASP effect, not one that is simple for us to forecast.
Glen,我想這可能是我們歷史上參與的醫師數量最多的一次,包含北美的矯正(ortho)與北美的全科(GP),以及國際市場。隨著我們的客戶基礎變得更廣,某種程度上也算是mix。這些醫師未必已經加入Advantage,或未必以與Advantage相同的程度參與,所以整體而言,更多的病例量與出貨來自那些低量客戶的醫師。因此這對ASP是正向效果,但對我們來說不容易精準預測。
Glen Santangelo - Analyst
Glen Santangelo - Analyst
Okay. And then, Ken, maybe if I could just kind of follow up. It seems like you backed off the share repurchase a little bit this quarter. What do you anticipate as you look out to the remainder of the year given the cash build you have?
好的。然後,Ken,如果我可以再追問一下。看起來你們本季稍微放慢了股票回購。考量你們現金累積的情況,展望今年剩餘時間你們預期會怎麼做?
Ken Arola - VP of Finance, CFO
Ken Arola - VP of Finance, CFO
So at this point we look at it from an opportunistic point of view. And when we feel that it is right to buy in the marketplace, we will be out there, and then I would probably just stop at that.
所以目前我們是以機會主義的角度來看。當我們覺得在市場上買進是合適的時候,我們就會進場,然後我大概就先說到這裡。
Glen Santangelo - Analyst
Glen Santangelo - Analyst
Okay. All right, thanks so much.
好的。好,真的非常感謝。
Operator
Operator
John Kreger, William Blair.
John Kreger,William Blair。
John Kreger - Analyst
John Kreger - Analyst
Could you just give us a little bit more of an update on the New Jersey consolidation practice, their progress for Cadent?
你們能否就新澤西整併作業的進度、以及對Cadent的進展,再多給我們一點更新?
Ken Arola - VP of Finance, CFO
Ken Arola - VP of Finance, CFO
Sure. We are actually about midway through the transition here. We have -- with our goal of being completed by the end of quarter three. We are making some good progress. We are on track with the various aspects of the transition. We are in the process of hiring folks down in Costa Rica as well as in Juarez for the transition and start to do cross training. We have actually started a lot of that because we manufactured a fair amount of volume for the restorative side of the business out of Juarez this quarter that we just completed. So things are on track, and anticipating at the end of Q3 we should be able to complete the transition.
當然。我們其實正處於這次轉換的中段左右。我們——目標是在第三季末完成。我們取得了不錯的進展。轉換的各個面向都在軌道上。我們也正在哥斯大黎加以及華雷斯(Juarez)招募人員,以支援轉換並開始交叉訓練。其實我們已經開始做了不少,因為在剛結束的這一季,我們在華雷斯為修復(restorative)業務端製造了相當多的量。所以一切都在軌道上,預期在第三季末我們應該能完成轉換。
John Kreger - Analyst
John Kreger - Analyst
Excellent, thanks. And how about an update on the sales strategy across both your core products and Cadent? How are the sales first handled, the second product line, have you seen any signs of distractions there?
太好了,謝謝。那你們在核心產品與Cadent之間的銷售策略方面,有沒有最新進展?銷售是如何先推第一個、再推第二個產品線?你們有看到任何分心的跡象嗎?
Tom Prescott - President, CEO
Tom Prescott - President, CEO
Well, I guess, as I said, our first criteria toward shareholders, our Board, was don't take our eye off the Invisalign ball, so I think that is the first place you should look to make sure we maintain focus on our game plan.
嗯,我想,如我所說,我們對股東、對董事會的第一個準則是,不要把注意力從Invisalign這顆球上移開,所以我認為你應該先看這一點,確認我們仍維持對既定計畫的專注。
The second is that we wanted to use the relationships we had with 20,000 plus customers in North America -- 25,000 customers in North America to at least introduce them to the idea for inter-oral scanner.
第二,我們希望運用我們在北美超過20,000位客戶——北美25,000位客戶——的關係,至少向他們介紹口內掃描器(inter-oral scanner)的概念。
Cadent had, I think, at the time of acquisition eight or nine reps and we have more than doubled that now. But more importantly, they are deployed in a way that has them working closely with each region for our Invisalign business.
我記得在收購時,Cadent大概有八或九位業務代表,而我們現在已經增加到兩倍以上。但更重要的是,他們的部署方式是讓他們與我們Invisalign業務的各區域團隊密切合作。
And so instead of driving around demoing individual offices, we use literally hundreds of Invisalign-focused events -- study clubs, workshops, training events, to -- in a very efficient way to introduce scanner and CAD/CAM services technology to GPs and orthos.
因此,我們不是到處開車逐一示範單一診所,而是實際上運用數百場以Invisalign為核心的活動——讀書會(study clubs)、工作坊、訓練活動——以非常有效率的方式,向全科醫師(GP)與矯正醫師(ortho)介紹掃描器與CAD/CAM服務技術。
That is working very, very well. The Invisalign reps don't have quotas for scanners, and scanner reps don't have quotas for Invisalign, but we find little ways to -- little spiffs and stuff to keep them interested. And more importantly, they love keeping scores at teams. So we are -- I think we are still in the early days. We're just -- next week will be a year in. But this is one area where we are -- where I would say we are ahead of our original plans.
這運作得非常、非常好。Invisalign業務代表沒有掃描器的配額(quota),掃描器業務代表也沒有Invisalign的配額,但我們會用一些小方法——一些小獎金(spiffs)之類的——讓他們保持興趣。更重要的是,他們很喜歡以團隊方式記分競賽。所以我們——我認為我們仍在早期階段。我們才——下週就滿一年。但在這個領域,我會說我們比原先的計畫更超前。
I think over time as we are able to scale what Cadent have for OrthoCAD services and those kinds of things, then we can start putting effort into building out the suite of other orthodontic opportunities, the OrthoCAD products and elsewhere.
我認為,隨著時間推移,當我們能夠把 Cadent 在 OrthoCAD 服務及這類業務的規模擴大之後,我們就可以開始投入資源,去建構其他正畸領域的機會組合,包括 OrthoCAD 產品以及其他方面。
Cadent was in a place where they really couldn't scale that business. They didn't have capacity, and I think as we bring Juarez and Costa Rica resources online and get through a few growing pains here, we will be able to think about how to drive not just scanner placement growth, but the services around that. So still very interested in doing that.
Cadent 當時的狀況是,他們其實無法把那項業務做規模化。他們沒有產能;我認為,當我們把華雷斯(Juarez)與哥斯大黎加的資源上線,並度過這裡的一些成長陣痛之後,我們就能思考如何推動的不只是掃描器裝機量的成長,還包括圍繞其上的服務。所以我們仍然非常有興趣去做這件事。
John Kreger - Analyst
John Kreger - Analyst
Great, thanks. And just one other question. It has been a few months since you launched the Express 10 product. Can you comment on the competitive traction that you are seeing there versus the new, I think, Clear Guide entrance?
很好,謝謝。另外還有一個問題。自從你們推出 Express 10 產品以來已經過了幾個月。你能否談談你們在那邊看到的競爭動能,相較於我想是 Clear Guide 的新進入者?
Tom Prescott - President, CEO
Tom Prescott - President, CEO
We literally shipped our first Express 5 case at the end of January. And feedback we're getting is very, very positive from the docs. It is still small, but it is growing nicely. And in general we are not seeing this be so much of an entry-level product. Instead it is a more experienced customer that says, I have a very, very mild malocclusion of space, a little bit of crowding. I can comfortably offer a very cost effective treatment to this patient that doesn't want comprehensive treatment or might have a very subtle relapse. And so that is more the initial uptake.
我們在一月底才剛出貨第一個 Express 5 案例。而我們從醫師那邊收到的回饋非常、非常正面。目前規模仍小,但成長得很不錯。整體而言,我們並沒有看到它主要被當成入門級產品。相反地,更多是較有經驗的客戶會說:我有一個非常、非常輕微的咬合不正或間隙問題,有一點點擁擠。我可以很有把握地為這位不想做全口矯正、或可能只是非常輕微復發的病患,提供一個非常具成本效益的治療方案。所以這比較是初期的採用情況。
I guess, I don't want to go into a lot of detail about how it lines up against Ormco's product offering. We have a lot of respect for Ormco as a company, and we will be able to shout at each other next week at AAO. But I think we are pretty comfortable with our overall offering with -- because for any five stages you can get, we should be able to do more treatment than anybody else in the world.
我想我不想深入談太多它與 Ormco 產品組合之間的對位比較。我們非常尊重 Ormco 這家公司,而下週在 AAO 我們也會有機會彼此「喊話」。但我認為我們對整體產品提供相當有信心——因為在任何五個階段的方案下,我們應該都能提供比全球任何人更多的治療能力。
John Kreger - Analyst
John Kreger - Analyst
Great, thanks.
很好,謝謝。
Operator
Operator
Matt Dolan, ROTH Capital Partners.
ROTH Capital Partners 的 Matt Dolan。
Matt Dolan - Analyst
Matt Dolan - Analyst
Congratulations. So clearly the numbers look great and this question partially depends on your sequential outlook for Cadent. But now that we have the first-quarter results in hand it would appear your guidance for Invisalign growth on a year-over-year basis is a little slower. So maybe you can comment, Tom, on what you are seeing in the environment there on a month-to-month basis throughout the year so far that would lead you to those Q2 numbers? Kind of following up on that earlier question about the sequential growth.
恭喜。很明顯數字看起來很漂亮,而這個問題部分取決於你們對 Cadent 的環比展望。但現在我們已經拿到第一季的結果,看起來你們對 Invisalign 年增成長的指引稍微慢一些。所以 Tom,也許你可以談談你們今年以來按月觀察到的市場環境,哪些因素讓你們給出第二季那些數字?算是延伸前面那個關於環比成長的問題。
Tom Prescott - President, CEO
Tom Prescott - President, CEO
I guess maybe I would ask Ken to jump in with a few details. I will come back and maybe make a few overarching comments about specific guidance on Q2.
我想也許我會請 Ken 先補充一些細節。我之後再回來,針對第二季的具體指引做一些更宏觀的說明。
Ken Arola - VP of Finance, CFO
Ken Arola - VP of Finance, CFO
Yes, gosh, you know, I guess my view of it is we are showing some, I think, pretty strong growth Q2 to Q2, 20 plus percent on a year-over-year basis. And coming off of a strong quarter one into quarter two, and even sequential growth was stronger than it normally is where you might look back and see Invisalign volumes growing 5% or 6% sequentially. Guidance is more in that 7% to 9% range.
是的,嗯,你知道,我的看法是,我們第二季對第二季的年增仍呈現相當強勁的成長,我想是 20% 以上。而且是在第一季表現強勁的基礎上進入第二季;甚至環比成長也比通常更強,過去你可能會看到 Invisalign 量環比成長 5% 或 6%。我們的指引是在 7% 到 9% 的區間。
So from my perspective, again, it goes back to the technology, the clinical efficacy of the product now. And things we are doing on the advertising front going into the teen summer, building up for the teenage case starts that start in the month of June basically, and getting ahead of that, and educating parents and moms and kids about Invisalign. So from my perspective I think 20% growth is pretty respectable on a year-over-year basis.
所以從我的角度來看,回到技術面、產品目前的臨床療效。以及我們在廣告端所做的事情,迎接青少年暑期旺季,為基本上從 6 月開始的青少年病例啟動做準備,並提前進行,教育家長、媽媽以及孩子們認識 Invisalign。所以以我的觀點,年增 20% 我認為是相當值得肯定的成長。
Matt Dolan - Analyst
Matt Dolan - Analyst
Yes, okay. And that is the first part of the question surrounding what Cadent was doing, which we don't have, so thank you.
好的。那是問題的第一部分,關於 Cadent 當時在做什麼——我們沒有那部分資訊,所以謝謝。
And then, secondly, on the operating expense side of things, it looks like last year your spend came off in Q3. I know you have talked about entering into the Olympic season and so forth this year. Can you walk us through the pacing of spend into the back half of the year, what we should expect after Q2? Thanks.
第二個問題是關於營業費用端,看起來去年你們在第三季的支出有下降。我知道你們今年談過會進入奧運季等等。你能否帶我們走一遍今年下半年支出的節奏,第二季之後我們應該期待什麼?謝謝。
Ken Arola - VP of Finance, CFO
Ken Arola - VP of Finance, CFO
Yes, let me frame it for you a little bit here. Last quarter we talked about adding in scanner sales force, and we have got the scanner sales team fully up to speed and up and running now. So that ought to level itself out as we move through the remainder of the year here, unless we add in on a spot basis someone here and there.
好的,我先幫你稍微框架一下。上季我們談到要增加掃描器的銷售人力,而我們現在已經讓掃描器銷售團隊完全上手並開始運作。所以在今年剩餘期間,這部分應該會趨於平穩,除非我們在個別情況下零星再增補一兩位。
The Invisalign sales team, we will be looking at expanding a couple of territories of the business. It is growing pretty significantly. We have got reps in territories that are twice the size of what they were several years ago. So we will have a few salespeople we will be feathering into the business over the second half of the year.
至於 Invisalign 銷售團隊,我們會考慮擴大業務的幾個區域。業務成長相當顯著。我們有些業務區域的規模是幾年前的兩倍。因此在下半年,我們會逐步把幾位業務人員補進來。
And the way with our advertising, we are pretty -- we'll be pretty heavy in Q2 here in advertising, much more than we were in quarter one. And in quarter three we will keep relatively strong with our advertising and fall off more in the fourth quarter again.
在廣告方面,我們在第二季的投放會相當——會相當重,比第一季高出許多。第三季我們會維持相對強勁的廣告力道,然後在第四季再度明顯回落。
Tom Prescott - President, CEO
Tom Prescott - President, CEO
Just (inaudible). With advanced purchases and a much more integrated media platform than just TV, and not in the old days having to buy remnants and spot, we are more buffered against a once every four-year that like a Summer Olympics. If I go back eight years or even four years it was easy to displace us. We have a much more integrated program now and we're working with different kinds of programs, like Disney, where we get access.
只是(聽不清)。透過提前採購,以及比起只做電視更整合的媒體平台,而不是像以前那樣必須買零散的剩餘時段與點位,我們對於像夏季奧運這種每四年一次的事件,其影響有更好的緩衝。如果我回頭看八年前甚至四年前,我們很容易被擠掉。現在我們的方案整合度高得多,也在與不同類型的節目合作,例如 Disney,讓我們能取得資源。
So certainly ad rates go up, and they will go up at the end of the year with the election. But we have a much more integrated platform, and we are a little more buffered against that effect.
所以廣告費率確實會上升,而且年底因為選舉也會上升。但我們有更整合的平台,因此對那種影響的緩衝能力更強一些。
Matt Dolan - Analyst
Matt Dolan - Analyst
So I guess just to clarify, the pattern we saw last year, should we not see that again this year?
所以我想確認一下,去年我們看到的那種模式,今年是不是不會再出現?
Ken Arola - VP of Finance, CFO
Ken Arola - VP of Finance, CFO
Well, the couple of items that occurred last year, if you recall, were we got behind in some hiring in the summer months. And that impacted some of our spending in relation to some of the marketing programs that we were trying to accomplish over in Europe for specifically.
嗯,去年發生的幾個項目,如果你還記得,是我們在夏季幾個月的招募進度落後了。那影響了我們在歐洲特定要推動的一些行銷計畫相關支出。
I think this year we have gotten back on track with some hiring, like I've mentioned. And I would hope that we don't get surprised on the short side of spending because we just haven't added the right amount of people at the right timing. But it is always a matter of finding the right person at the right time to bring on board.
我想今年我們已經把部分招募拉回正軌,就像我提到的。我希望我們不會在支出上出現偏低的意外,原因只是我們沒有在對的時間點補進足夠的人力。但這始終取決於能否在對的時間找到對的人加入。
Matt Dolan - Analyst
Matt Dolan - Analyst
Okay, thanks a lot.
好的,非常謝謝。
Operator
Operator
Steve Beuchaw, Morgan Stanley.
Morgan Stanley 的 Steve Beuchaw。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
Thanks for taking the questions everyone. I wanted to drill down just a little bit on the number of users in the quarter and the growth of that base. The growth rate for that user base is -- as far as I can tell, it is at or near an historic high. But can you speak to the sustainability of that rate of growth, of that user base? Can we see more double-digit growth over the balance of the year?
謝謝各位回答問題。我想稍微深入一下本季使用者數量以及該基礎的成長。就我看來,該使用者基礎的成長率——已經達到或接近歷史高點。但你能否談談這個使用者基礎成長率的可持續性?今年剩餘期間我們是否還能看到更多的雙位數成長?
Tom Prescott - President, CEO
Tom Prescott - President, CEO
That is -- it is a good question. We are not -- that is a bit more of an outcome than a design criteria for us. Let me explain what I mean by that. The number we focus on a little more is new doctors trained. And we have to work around when they want to be trained.
沒錯——這是個好問題。我們並不是——對我們而言,那更像是一個結果,而不是設計準則。我來解釋一下我的意思。我們更關注的數字是受訓的新醫師人數。而且我們必須配合他們想要受訓的時間。
We deliver CE1 training to interested new doctors at a time when they are willing to travel and go for a place for a weekend, etc. So, for example, early in Q1 or late in Q4 not available, parts of the summer not available.
我們會在新醫師願意出行、願意週末到某個地方上課等的時間,向有興趣的新醫師提供 CE1 訓練。所以例如,第一季初或第四季末不方便,夏季的某些時段也不方便。
So every year we budget, if you will, number of courses and number of new doctors and then we market to them and sign them up. And we are on track but that in general.
因此每年我們會編列預算(如果你願意這麼說的話),規劃課程數量與新醫師人數,然後向他們行銷並完成報名。而我們整體而言都在軌道上。
The second part of that is -- and then we train doctors in their dental schools or coming out of ortho departments or whatever. And then the second part of that is how quickly we are able to engage doctors to start doing cases. And these lower-volume doctors might be out of it for a couple of quarters and then come back in with two or three cases.
第二部分是——接著我們會在牙醫學院、或從齒顎矯正科系出來的醫師等各種管道訓練醫師。然後第二部分是,我們能多快讓醫師開始接案做病例。而這些低量醫師可能會有幾個季度不做,之後又回來做兩三個病例。
So in this case there are two effects. One we can control, which is the new doctor training. And by pointing them towards Assist and giving them incentives to do more cases soon, meaning, we want them to get some repetitions and get to use the product so they will know how to do it, that is working better and better.
所以在這個情況下有兩個影響因素。其中一個是我們可以控制的,也就是新醫師訓練。透過引導他們使用 Assist,並提供誘因讓他們更快做更多病例——也就是說,我們希望他們多做幾次、實際使用產品,這樣他們就會知道怎麼做——這件事的效果越來越好。
The docs that are coming back to the game, are -- that patients are asking about, those are all positive things, but we can't necessarily predict that as well as we can with new doctors starts.
至於那些回到市場的醫師——以及病患正在詢問的那些——這些都是正面的事情,但我們未必能像預測新醫師起案那樣精準地預測。
So as true sustainability, we are going to get variability quarter to quarter. We worry less about that and more about the core utilization and the repeat customers that we have, and those are all going in the right direction.
因此就真正的可持續性而言,我們的季度表現會有一定的波動。我們比較不擔心這點,而是更關注核心使用率與我們既有的回購客戶,而這些都在朝正確方向發展。
So all these newer doctors and less involved doctors for us, that is just gravy; it is wonderful. We will take it, and now we are going to build and our [momentum].
所以對我們而言,這些較新的醫師與參與度較低的醫師,都是額外的加分;非常棒。我們會欣然接受,現在也會在此基礎上建立並延續我們的[動能]。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
That is really helpful. Thanks, Tom. And then one question on the broader dental markets in the quarter, I mean, thinking about this very broadly, outside of just the clear aligner space. I wonder if you could spend a little bit more time on your views on inpatient flows in dentistry in the US?
這真的很有幫助。謝謝你,Tom。接著有一個關於本季更廣泛牙科市場的問題,我的意思是,從非常宏觀的角度來看,不只是在透明矯正器領域。我想請你多花一點時間談談你對美國牙科門診病患流量的看法?
And I ask the question because one of the major dental players last week gave a more conservative view of the volume picture there. So any color you could give that would help reconcile the comments would be really helpful. Thanks everyone.
我之所以問,是因為上週其中一家主要牙科業者對那邊的量能走勢給出了較保守的看法。所以如果你能提供一些補充說明,幫助我們把這些評論對起來,會非常有幫助。謝謝各位。
Tom Prescott - President, CEO
Tom Prescott - President, CEO
Sure, well, we have referenced a series of things, two of which are proprietary; one that is available out there with a third party. The third-party piece that is available out there I talked about you have both -- dentists will be the first to admit they aren't the best forecasters in the world. But the way to get at that is to look at their calendars and their schedule books and their appointments and then the actual volume of procedures they are seeing against, say, a period a year ago or a quarter ago.
當然,我們曾提到一系列事項,其中兩項是專有資料;另一項是可透過第三方取得的資料。至於外部可取得的第三方資料,我提過你同時會看到——牙醫自己也會先承認,他們不是世界上最好的預測者。但要切入這點的方法,是看他們的行事曆、排程本、預約情況,然後再看實際的處置量,對比例如一年前或上一季的期間。
And when those elements collectively are positive, their attitudes are fundamentally different. And that is probably the most important secular trend for us in dentistry is are our customers or the doctors more confident that their business is going in the right direction, that patients are coming in, and they are more amenable to considering higher value procedures.
當這些要素整體呈現正向時,他們的態度在根本上就會不同。而對我們在牙科領域而言,最重要的長期趨勢大概就是:我們的客戶——也就是醫師——是否更有信心認為他們的業務正朝正確方向前進、病患正在進來,並且更願意考慮較高價值的療程。
All of the indicators we are seeing, these aren't sharply up, but they are directionally up, and that is all a good thing. And the reason why there is more leverage for us there compared to, say, more the traditional consumables players is that it doesn't take much of a move around attitude for the dentists and their practice to be much more comfortable. The patients are already there, but for them to be much more comfortable in offering these higher-value procedures.
我們看到的所有指標,雖然不是大幅上升,但方向上是往上走的,這都是好事。而我們相較於例如較傳統的耗材業者之所以更有槓桿,是因為牙醫的態度只要稍微變動一下,他們與診所就會更安心。病患其實已經在那裡了,但他們會更願意提供這些高價值的療程。
And so, again, the first secular trend we watch is relative attitudes and outlook and confidence about the future state. We know that our GP dentists and our orthos will be more likely to offer higher-value procedures like Invisalign if their attitudes are positive. And it is just the opposite on a downside. Again, small changes, up or down, have a pretty big impact the way they behave.
因此再說一次,我們觀察的第一個長期趨勢是:相對的態度、展望與對未來狀態的信心。我們知道,如果態度正向,我們的一般牙醫(GP)與矯正專科(ortho)就更可能提供像 Invisalign 這樣的高價值療程。而在下行時則正好相反。同樣地,無論上或下,小幅變化都會對他們的行為造成相當大的影響。
So, again, I think we will know more. We will get a read through when DENTSPLY reports, when [Patterson & Shine] report. We aren't the proxy for broad dentistry. But again, we are extremely under-penetrated. And the first time for us, especially among our dentists, is when they have positive attitudes about the quarter ahead, the year ahead, and that is what gives them the most confidence to move forward.
所以再說一次,我想我們之後會知道得更多。當 DENTSPLY 公布、以及 [Patterson & Shine] 公布時,我們會得到更多線索。我們並不是整體牙科市場的代理指標。但再說一次,我們的滲透率仍然非常低。而對我們而言,尤其是在一般牙醫族群中,當他們對接下來一季、接下來一年抱持正向態度時,這是他們最有信心往前推進的時候。
Operator
Operator
Spencer Nam, ThinkEquity.
Spencer Nam,ThinkEquity。
Spencer Nam - Analyst
Spencer Nam - Analyst
Thanks for taking my question. I just have two quick questions for you guys. The first one is, if we didn't have G3 and G4, I know that is a hypothetical situation since you guys have those, how would be Invisalign -- the original, if you will, would -- case volume would look like year-over-year? How would you characterize that volume growth if there is any?
謝謝讓我提問。我只有兩個很快的問題。第一個是,如果我們沒有 G3 和 G4——我知道這是假設性的情境,因為你們確實有——那麼 Invisalign——也就是原始版本(如果你願意這麼說)——其病例量的年對年會是什麼樣子?如果有成長,你會如何描述那個量的成長?
Tom Prescott - President, CEO
Tom Prescott - President, CEO
I guess I am just thinking about the best way to deal with it hypothetically. Hypothetically, we had a basis for looking at growth years ago. And the reasons why doctors didn't do certain cases was because they didn't think they could get the right finishes. Removing those reasons by giving them the ability to get those -- treat those more complex cases, get those finishes, is exactly what is driving utilization growth.
我想我是在思考,用假設的方式要怎麼處理這個問題最好。假設來說,我們在多年前有一個用來觀察成長的基準。而醫師之所以不做某些病例,是因為他們認為無法達到理想的最終效果。透過讓他們有能力處理那些——治療更複雜的病例、達到那些最終效果——來移除這些原因,正是推動使用率成長的關鍵。
So I guess you would look back three, four or five years and say, while there is still an appetite for consumers and patients, there were good reasons for practices not to do more complex cases, and we are taking those down.
所以我想你可以回頭看三、四或五年前,並說,雖然消費者與病患仍有需求,但診所不做更複雜病例是有合理原因的,而我們正在把這些障礙移除。
So G3 and G4 and the latest there is going to be a lot more of that to come, and we intend to be a brutally efficient competitor here at bringing technology like this forward.
所以 G3、G4,以及最新的——未來還會有更多這類技術推出——而我們打算在把這類技術推向市場方面,成為一個極度高效率的競爭者。
Spencer Nam - Analyst
Spencer Nam - Analyst
So are you seeing -- still seeing increased growth in the regular Invisalign cases relative to the previous year?
所以你們是否仍然看到一般 Invisalign 病例相較於前一年有更高的成長?
Tom Prescott - President, CEO
Tom Prescott - President, CEO
Well, yes, I will remind you that G3 and G4 is embedded completely into every product, whether it is Express 5 or whether it is Teen or whether it is Full or Assist. And so the question that came up earlier about competitor pressure with another product is for any length of treatment we are going to bring the best technology possible, which should give you the most movement per stage, the most predictable case, the best finish.
嗯,是的。我提醒你,G3 和 G4 已經完全內嵌到每一個產品中,不論是 Express 5、Teen、Full 或 Assist。因此先前提到的、關於競品壓力與另一個產品的問題是:不論療程長短,我們都會導入最好的技術,這應該能帶來每一階段最大的移動量、最可預測的病例,以及最好的最終效果。
So we literally have -- we want our best technology, G4, G5, whatever is coming next into every single case. That is what is creating greater predictability. That is what is giving confidence to docs, and that is what is leading to increased utilization.
所以我們確實——我們希望把我們最好的技術,G4、G5 或接下來的任何版本,放進每一個病例裡。這就是在創造更高的可預測性。這就是在給醫師信心,而這也正是帶動使用率提升的原因。
Spencer Nam - Analyst
Spencer Nam - Analyst
I see. That is helpful. And then just a second quick question. Any update on China, where it is at? What kind of stage you guys are at in terms of pushing the product through the markets out there -- or any update would be great?
我了解。這很有幫助。接著再快速問一個問題。中國那邊有什麼最新進展嗎?目前進度到哪裡了?你們在把產品推進當地市場方面處於什麼階段——任何更新都很棒。
Tom Prescott - President, CEO
Tom Prescott - President, CEO
Sure, I will keep it simple. China is one of the few countries we think -- individual countries that offers the same kind of size potential as say the US does. So we are taking a very, very thoughtful, careful approach to building the right base, ensuring that our research and clinical education partners at the major universities there are treating a lot of cases and getting that case experience.
當然,我簡單說明。中國是少數幾個我們認為——就單一國家而言——具備與美國相當規模潛力的市場。因此我們正以非常、非常審慎且周全的方式來建立正確的基礎,確保我們在當地主要大學的研究與臨床教育合作夥伴能夠治療大量病例並累積病例經驗。
By definition, they are much more complex cases. And many of them are 2, 2.5 years long or more. And as we get that foundation built over the next year or two, I think we are going to be in a position to step on the gas a little bit. But we believe this will be a contributor to growth in the mid to long term and not in the near term. But again, we are taking a thoughtful and very organized and disciplined approach to building the business there.
按定義來說,這些都是更複雜的病例。而且其中很多療程長達2年、2.5年或更久。隨著我們在未來一到兩年把這個基礎打好,我認為我們會有條件稍微加速。但我們相信這會在中長期而非短期成為成長的貢獻來源。不過再次強調,我們正以周全、非常有組織且自律的方式在當地建立業務。
Spencer Nam - Analyst
Spencer Nam - Analyst
Thank you.
謝謝。
Operator
Operator
Jonathan Bloch, SunTrust.
Jonathan Bloch,SunTrust。
Jonathan Block - Analyst
Jonathan Block - Analyst
Maybe the first one just on gross margin. I think your Invisalign gross margin of 79%, I believe was the highest -- I don't know if in the Company's history but maybe the past four or five years. So if you can give some comments there. You're doing more complex cases. You think that would be more aligners and maybe somewhat cap the margin, but yet we see it continue to trend higher. Where do these go or can you talk to directionally once you conclude most of the ongoing initiatives that are taking place in Juarez right now? Thanks.
第一個問題可能是關於毛利率。我想你們 Invisalign 的毛利率是79%,我相信這是最高——我不確定是否是公司史上最高,但可能是過去四、五年來最高。所以想請你們評論一下。你們在做更多複雜病例。你會認為這會需要更多副牙套,可能在某種程度上限制毛利率,但我們卻看到它持續走高。這會往哪個方向走?或者你能否從趨勢上談談,一旦你們完成目前在華雷斯(Juarez)進行的大部分持續性計畫之後會如何?謝謝。
Ken Arola - VP of Finance, CFO
Ken Arola - VP of Finance, CFO
This is Ken. So one of the biggest factors here really of overall gross margin is the volume of the product going through the factory. If -- as we are doing more complex cases, you may have a few aligners per case of an increase, but that gets compensated when we saw that the volume that went through the factory this past quarter to actually drive gross margins up a bit here.
我是 Ken。這裡影響整體毛利率的最大因素之一,其實是產品通過工廠的產量。如果——當我們做更多複雜病例時,每個病例可能會多幾副牙套,但當我們看到本季通過工廠的產量提升時,這會抵消並實際推動毛利率略為上升。
And that is what you see in the business pretty routinely. If volumes move up pretty significantly in a quarter, we are relatively fixed cost in the factory overall, at least in the near term, so you see the leverage of not showing up right away in the P&L.
而這在業務上你會相當常見地看到。如果某一季的產量顯著上升,我們工廠整體在短期內相對屬於固定成本,因此你會看到槓桿效益不會立刻在損益表上反映出來。
And on an ongoing basis, I would say the operation guys -- they are continuously looking for ways to optimize the manufacturing process, continue to get cost out. They have obviously done a great job over the last four or five years, but that there is still more opportunity.
另外就持續性而言,我會說營運團隊——他們一直在尋找優化製造流程、持續降低成本的方法。他們在過去四、五年顯然做得非常好,但仍然還有更多機會。
Jonathan Block - Analyst
Jonathan Block - Analyst
Okay, and then just my follow-up question there. Ken, would just be -- so I am making sure that I am understanding you correctly. There are duplicative costs right now that you are carrying in your non-GAAP gross margin from the Juarez initiative, is that correct?
好的,那我接著追問一下。Ken,我只是想確認我理解正確。你們目前在非 GAAP 毛利率中,因華雷斯計畫而承擔了重複性的成本,這樣說對嗎?
Ken Arola - VP of Finance, CFO
Ken Arola - VP of Finance, CFO
That is correct. We still have people in New Jersey and we still have -- we are hiring people in Juarez and in Costa Rica for that transition. So we have duplicative cost not only in people but in facilities costs.
沒錯。我們在新澤西仍然有人員,同時——我們也在華雷斯與哥斯大黎加為了這次轉移而招募人員。所以我們不僅在人員上有重複成本,在設施成本上也有重複成本。
Tom Prescott - President, CEO
Tom Prescott - President, CEO
Yes, the same thing for Invisalign, yes.
是的,Invisalign 也是同樣的情況,是的。
Jonathan Block - Analyst
Jonathan Block - Analyst
Okay, great. And then maybe just to shift gears for a second. You just talked to China and still think about that as longer term. But you have done a great job ramping a lot of your trained doctors in the various EMEA countries. And maybe you if can speak to what is going on over there, how that has been ramping up? And even if you can provide us with maybe an EMEA growth rate or Europe versus non-Europe growth rate would be very helpful. Thanks, guys.
好的,很好。那接著換個話題。你剛才談到中國,仍然把它視為較長期的機會。但你們在各個 EMEA 國家把受訓醫師的規模拉升做得很出色。也許你可以談談那邊的情況、目前是如何加速成長的?甚至如果你能提供 EMEA 的成長率,或歐洲與非歐洲的成長率對比,會非常有幫助。謝謝各位。
Tom Prescott - President, CEO
Tom Prescott - President, CEO
So just to play it back -- make sure I got the question. You are wanting -- you're passing China. You are wanting to go look at Europe versus our distributor geography specifically?
我先複述一下——確認我理解你的問題。你想先略過中國。你想看的是歐洲相對於我們經銷商地理區域的表現,特別是這個對比?
Jonathan Block - Analyst
Jonathan Block - Analyst
Exactly. I want to know what is going on from a case volume perspective. You have gone from just a handful of trained docs to -- I got to look at my (inaudible) -- 400 or 500 trained docs in EMEA over the past several months. So how do you see that business evolving over the next 12 to 24 months? Thanks.
沒錯。我想知道從病例量的角度來看發生了什麼。你們在 EMEA 的受訓醫師從只有少數幾位,增加到——我得看一下我的(聽不清)——在過去幾個月已經有400或500位受訓醫師。所以你怎麼看這項業務在未來12到24個月的演變?謝謝。
Tom Prescott - President, CEO
Tom Prescott - President, CEO
Well, first of all, not just EMEA, which is starting -- with an existing business and ramping up in Russia and other places, but we expect Asia-Pacific had basically been outstripping all of them to continue to grow very nicely. We have got critical mass in a whole set of countries, and we expect that to continue.
嗯,首先,不只是 EMEA——那邊是在既有業務基礎上,在俄羅斯和其他地方加速擴張——但我們預期亞太地區基本上一直領先其他地區,並將持續非常不錯地成長。我們在一整組國家已經達到關鍵規模,我們預期這會持續下去。
Their volume is growing faster than even Europe's volume or North America. So in general between the three of them, Asia-Pacific, Latin America and EMEA, we expect collectively the volume to grow to outstrip by a little or a lot what we are seeing in Europe, which is healthy.
他們的量成長甚至比歐洲或北美還快。因此整體來看,在這三個區域——亞太、拉丁美洲與 EMEA——我們預期合計的量成長會略高或顯著高於我們在歐洲看到的表現,而歐洲本身也很健康。
So if you just lay that line out five years, we would say that the nondirect volume outside US is going to continue to take a larger piece of the total volume. And we expect -- but we expect in that order, distributor rates to grow faster than international than US, and yet all of them collectively are growing pretty nicely. So I don't see a reason why that would continue.
所以如果把這條趨勢拉長到五年,我們會說美國以外的非直營量將持續在總量中占比提高。而且我們預期——但我們預期依序來看,經銷商市場的成長率會快於國際直營市場,而國際直營又會快於美國;但三者合計都成長得相當不錯。所以我看不出有什麼理由不會延續下去。
Part of that is new doctor training. But I would remind you that a lot of that is the cases that get treated outside the US are generally far more complex than what gets treated in the US. In Asia specifically and parts of Europe, you are dealing with far more complex facial structural change and Class II and Class III cases. So the G3, G4, etc., really plays to that. That is part of what is helping us pick up incremental volume.
其中一部分來自新醫師訓練。但我也要提醒你,美國以外治療的病例通常比美國治療的病例複雜得多。特別是在亞洲以及歐洲部分地區,你會面對更複雜的顏面結構改變,以及第二類(Class II)與第三類(Class III)病例。因此 G3、G4 等產品其實很契合這些需求。這也是幫助我們取得額外量的一部分原因。
Jonathan Block - Analyst
Jonathan Block - Analyst
Okay, so the follow-up to that one would be, real quick, over the next 1 to 2 years think about more of distributor impact on incremental from an international standpoint, China would be more year, two-year, three and beyond?
好的,那針對這點的追問是:很快地,未來1到2年,從國際角度看,增量中更多會來自經銷商的影響;而中國會比較偏向第1年、第2年、第3年以及更往後嗎?
Tom Prescott - President, CEO
Tom Prescott - President, CEO
I think what you're seeing right now is exactly what you should expect in the nearer term, volume growing faster. And certainly with the discount, the revenue growth is a little slower, but volume growing faster in distributor geographies, and then Europe growing faster. I think we are going to restage growth in Europe as we are already seeing. And then North America continue to do pretty darn well, so high-quality problems.
我認為你現在看到的,正是你在較近的期間應該預期的情況:量成長更快。當然因為折扣的關係,營收成長會稍慢一些,但在經銷商地區是量成長更快,然後歐洲成長更快。我認為我們會重新帶動歐洲的成長,我們已經開始看到這點。而北美也會持續表現相當不錯,所以這些都是高品質的問題。
Jonathan Block - Analyst
Jonathan Block - Analyst
Thanks guys.
謝謝各位。
Operator
Operator
Jeffrey Warshauer, Sidoti & Company.
Jeffrey Warshauer,Sidoti & Company。
Jeffrey Warshauer - Analyst
Jeffrey Warshauer - Analyst
I was just hoping you guys could add a little bit more color to your international scanner revenue, looking at the first two quarters you had the business versus the last two?
我只是希望你們能對國際掃描儀營收再補充一些細節,對照前兩季的業務與後兩季的表現?
Ken Arola - VP of Finance, CFO
Ken Arola - VP of Finance, CFO
Well, the scanner business, we have -- as far as volume is concerned, we are continuing to work through our third-party distributor, Straumann, with them. And like we said last square, working with them to try to get growth going again in Europe with scanners.
嗯,關於掃描器業務,就出貨量而言,我們持續透過第三方經銷商 Straumann 與他們合作。而且就像我們上次所說的,我們正與他們合作,嘗試讓歐洲的掃描器業務重新恢復成長。
On the services side of the business, it has been a little bit slower as well the last couple of quarters. And that has to do -- a combination with the economy and also just the fact that scanner placements are a bit slower in Europe than they have been in North America. Where North America we have been right on track with our -- and maybe even ahead of our view of what is going on with scanner placements in North America and getting some good traction with the sales force.
在業務的服務端,過去幾個季度也稍微放緩了一些。這與經濟環境有關——同時也因為歐洲的掃描器裝機速度比北美慢一些。至於北美,我們的掃描器裝機進度一直符合我們的預期——甚至可能還略超前——而且銷售團隊也取得了不錯的進展。
Tom Prescott - President, CEO
Tom Prescott - President, CEO
I would maybe amplify that a little bit. The network of labs and the services flow around a scanner -- many of the scanners we have sold to at this state and this point have been orthodontically focused in Europe. And the lab infrastructure is different country by country and certainly different for North America. So that we think the stream of services around the scanner varies. It is probably -- it could be maximized North America and some European countries. In other countries they are saying the lab opportunities don't exist.
我可能再補充說明一下。圍繞掃描器的技工所網路與服務流——在歐洲,我們目前在這個階段賣出的許多掃描器更偏向矯正用途。而且各國的技工所基礎設施不同,當然也與北美不同。因此我們認為,圍繞掃描器的服務流會有所差異。在北美以及部分歐洲國家,這部分可能可以被最大化。但在其他國家,他們表示並不存在技工所方面的機會。
So I would say that part of the reason why we put most of the focus on go to market initiatives and bundling initiatives was directly for that reason in North America. For every installed base unit in a GP's office there are more opportunities to drive value to help the dentist office drive productivity, and for us to get rewarded for that by getting some more revenue and margin out of it in North America versus other geographies.
所以我會說,我們之所以把大部分重點放在上市(go-to-market)策略與綑綁(bundling)方案上,正是因為北美的這個原因。對於一般牙醫(GP)診所內的每一台已安裝設備,都有更多機會創造價值,協助牙科診所提升生產力;而我們也能因此在北美相較其他地區獲得更多收入與毛利作為回報。
That is still where most of our effort is. We are very supportive and working with our partners Straumann in a difficult environment to place more capital. But also mindful that the services stream around those scanners is a bit lighter. And as we scale the business better on the former Cadent side, we think we will be able to grow the services side, which is a bit of a perpetuity over time, even faster. But we are -- as I said, we are coming up on your one here and we've got a lot more work to do.
這仍然是我們投入最多心力的地方。在艱困的環境下,我們也非常支持並與合作夥伴 Straumann 一起努力,推動更多資本設備的裝機。但同時也注意到,圍繞這些掃描器的服務收入流相對較弱。而隨著我們在原 Cadent 端把業務規模化做得更好,我們認為將能更快地成長服務端業務——這部分長期來看有點像永續年金(perpetuity)。不過——如我所說,我們才剛進入第一年,還有很多工作要做。
Jeffrey Warshauer - Analyst
Jeffrey Warshauer - Analyst
Great, that is helpful. And looking at just Q1 Cadent revenue, the deferred revenue aside, how much of that do you think was pushed out from Q4?
很好,這很有幫助。再看一下第一季 Cadent 的營收,先不談遞延收入,你認為其中有多少是從第四季延後到第一季的?
Ken Arola - VP of Finance, CFO
Ken Arola - VP of Finance, CFO
You mean, decisions to differ capital purchased?.
你的意思是,客戶決策延後資本設備採購嗎?
Jeffrey Warshauer - Analyst
Jeffrey Warshauer - Analyst
Correct.
對。
Tom Prescott - President, CEO
Tom Prescott - President, CEO
Boy, I don't know. It is too early. I think it would have false precision calling that. We don't get great information from a customer if they decide to close and take possession in January or February versus November or December. Maybe when we have been at this for a while longer, we will have a better view of that, but I don't know that we would have any commentary on that at this point.
哎,我不知道。現在還太早。我覺得要去估那個數字會是虛假的精準(false precision)。如果客戶決定在 1 月或 2 月成交並交付,而不是在 11 月或 12 月,我們不會從客戶那裡得到很好的資訊。也許等我們做久一點會有更好的判斷,但目前我想我們沒有任何可評論的內容。
Jeffrey Warshauer - Analyst
Jeffrey Warshauer - Analyst
Okay, great. Thanks a lot.
好的,很好。非常感謝。
Operator
Operator
Jose Haresco, JMP Securities.
Jose Haresco,JMP Securities。
Jose Haresco - Analyst
Jose Haresco - Analyst
First, actually it has been a very good quarter. Secondly, could you give us a sense for where you think you guys are in terms of having penetrated the teenager market with Invisalign Teen? I know you talk about Invisalign as teenagers who are using Invisalign, but particularly around Teen as a product, where do you think you guys are in penetrating the market right now?
首先,這其實是一個非常好的季度。其次,你們能否讓我們了解一下,你們認為 Invisalign Teen 在青少年市場的滲透率目前大概到哪個程度?我知道你們會談到使用 Invisalign 的青少年,但特別就 Teen 這個產品而言,你們認為目前市場滲透到什麼程度?
Tom Prescott - President, CEO
Tom Prescott - President, CEO
Well, in terms of units, the numbers we use have been pretty consistent. And, again, once we waterfall out the cases that are too complex for us to even be in the discussion for, or the younger kids, we come back with a unit share of around 3% to Teen worldwide. So we really view that we have a lot of headroom for growth there for Teen, which is part of the reason for the focus.
嗯,就出貨量(units)而言,我們使用的數字一直相當一致。而且同樣地,當我們把那些對我們而言過於複雜、甚至無法納入討論的病例,以及更年幼的孩子排除後,我們回推得到 Teen 在全球的單位市占率大約是 3%。所以我們確實認為 Teen 還有很大的成長空間,這也是我們聚焦的部分原因。
Jose Haresco - Analyst
Jose Haresco - Analyst
Sure. Can you break that 3% out US versus OUS?
了解。你能把這 3% 拆成美國與美國以外(OUS)嗎?
Tom Prescott - President, CEO
Tom Prescott - President, CEO
Today it is more US than not. And again, we are disadvantaged a bit more OUS because in many of those countries there are formal reimbursement programs, which only reimburse brackets and wires or traditional treatments. Some of those are going away over time but, again, I think 3% in terms of unit share is a number that we always get to.
目前美國占比更高。同樣地,在許多美國以外的國家,我們相對更吃虧一些,因為那裡有正式的給付/報銷制度(reimbursement programs),而這些制度只給付托槽與鋼線或傳統治療。其中一些制度會隨時間逐步取消,但同樣地,就單位市占率而言,3% 是我們一直會得到的數字。
Jose Haresco - Analyst
Jose Haresco - Analyst
Okay. You talked about some of the advertising spend and continue to work with Disney. We have seen your advertising get a lot more effective since the product first launched. Could you walk us through what is working for you out there in terms of -- plus all your marketing efforts, and where have you seen the need perhaps to recalibrate what you're doing and who you're marketing to with regard to the teenage market and driving demand there?
好的。你提到一些廣告投放,並且持續與 Disney 合作。我們看到自產品剛推出以來,你們的廣告效果變得更好。你能否帶我們了解一下,在你們所有行銷努力中,哪些做法在市場上對你們有效?另外,你們在哪些地方看到需要重新校準你們的作法,以及在青少年市場方面你們要對誰行銷、如何帶動需求?
Tom Prescott - President, CEO
Tom Prescott - President, CEO
So I think you have seen us adjust over the last year or two -- two years, is a few years ago we, in terms of events, in terms, which is part of our platform, in terms of ads, we were facing some research were going much more after the teen as decision-maker. And the fact is for this purchase, for many purchases, teens are decision-makers.
我想你已經看到我們在過去一到兩年——兩年——做了調整。幾年前,我們在活動、以及作為我們平台一部分的廣告等方面,根據一些研究結果,更傾向把青少年當作決策者來溝通。而事實是,對於這項購買,以及許多購買,青少年確實是決策者。
For this purchase mom typically is still the decision-maker. And so we are advertising to moms and teens and that changes your tone on a lot of things.
但對於這項購買,通常媽媽仍然是決策者。因此我們同時對媽媽與青少年投放廣告,而這會改變你在很多事情上的語氣與訴求。
Along the way we can still advertise to mom, appeal to her own interest in having a better smile, and also position Teen. So that is one adjustment, and that plays out through a lot of different programs, and a lot of different approaches and pieces of the mix.
在這個過程中,我們仍然可以對媽媽投放廣告,訴求她自己想要更好笑容的需求,同時也定位 Teen 產品。所以這是一項調整,而它會反映在許多不同的專案、不同的方法與組合中的各個環節。
Secondly, we are far more balanced. If I go back three years, certainly five years, we were much more push versus pull. We have a very complimentary and balanced mix of PR and traditional advertising and radio and optimized search and social media, and a whole range of other tools that allows us to make the sum more effective than the parts.
第二,我們的組合更為均衡。如果回到三年前,甚至五年前,我們更偏向推(push)而不是拉(pull)。現在我們有非常互補且平衡的組合,包括公關(PR)、傳統廣告、廣播、最佳化搜尋、社群媒體,以及一整套其他工具,讓整體效果大於各部分之和。
Five years ago we were pretty much media, and now we even have some high-end print and all those things together. And so for every incremental dollar we can get a bigger kick than we would if we were just using one part of the platform.
五年前我們幾乎就是投放媒體,而現在我們甚至也有一些高端平面印刷媒體,所有這些一起運作。因此,每增加一美元的投入,我們能得到更大的回報力道(kick),而不是只使用平台中的單一部分。
And then, finally, we can actually -- we track this internally for cost per lead, cost per qualified lead, conversion rates and all that, and all those elements continue to get better and better. With advertising and marketing you always know you're leaving money on the table, but our net effectiveness continues to get a lot better.
最後,我們其實——我們在內部追蹤每條線索成本(cost per lead)、合格線索成本(cost per qualified lead)、轉換率等指標,而這些要素都持續變得越來越好。做廣告與行銷你永遠知道自己還有錢沒賺到,但我們的整體淨效益持續大幅提升。
Jose Haresco - Analyst
Jose Haresco - Analyst
Okay, great. Thank you very much.
好的,很好。非常感謝。
Shirley Stacy - VP, Corporate and Investor Communications
Shirley Stacy - VP, Corporate and Investor Communications
Operator, we will take one last question please.
接線員,我們請最後一個問題。
Operator
Operator
Jeffrey Matthews, Ram Partners.
Jeffrey Matthews,Ram Partners。
Jeffrey Matthews - Analyst
Jeffrey Matthews - Analyst
So what do you ascribe the pick up in low-volume doctors last quarter? Is it something you have done to -- what you have done to the product or is it more about Invisalign becoming a standard of care or is it random noise or something else?
你們如何解釋上季低量醫師(low-volume doctors)數量的回升?是因為你們對產品做了什麼?還是 Invisalign 正逐漸成為標準治療(standard of care)?或只是隨機雜訊(random noise)或其他原因?
Tom Prescott - President, CEO
Tom Prescott - President, CEO
I hope it is not random noise. I think it is a set of things. Someone asked a question earlier about primary demand. What we do know is that when the fundamental conditions get better in dentistry it really helps us. Maybe the way I would say this is when things are lousy we do better than most, and when things are good, we do better than most.
我希望不是隨機雜訊。我認為是多項因素的組合。先前有人問到初級需求(primary demand)。我們確實知道,當牙科產業的基本條件變好時,這對我們非常有利。也許我會這樣說:當景氣很差時,我們表現比大多數人好;當景氣很好時,我們也比大多數人好。
That is an okay kind of outcome for us. But in this case, especially with GPs, if you saw the number of say lower-volume GPs that came in, they are having the confidence to come in and start cases that if they bring up this topic their hygiene staff, the doctor -- the patients are more willing to engage with them in that idea about treatment, or if patients raise the topic with them they are more comfortable to move forward.
那對我們來說算是可以接受的結果。但在這個案例中,尤其是對一般牙醫(GP)而言,如果你看到例如一些低量能的 GP 進來的數量,他們更有信心進來並開始病例;如果他們把這個主題帶給他們的口腔衛生人員,醫師——病患更願意就治療的想法與他們互動;或者如果病患主動跟他們提起這個主題,他們也更自在地往前推進。
The second thing is, and we hear this in some of our research, is that when the orthodontist -- years ago when the orthodontist said Invisalign doesn't really work, it really -- there is a negative halo effect for the GPs. It took years to dig out of that.
第二點是——我們在一些研究中也聽到——當年矯正專科醫師說 Invisalign 其實沒什麼用、真的——這對 GP 造成了負面的光環效應。花了好幾年才走出那個陰影。
orthos, even those orthos that don't choose to do much with us are saying, you know, this product is actually really working. I'm not sure it is for me, but this thing actually really works. I amazed with what I am seeing.
矯正專科醫師,甚至那些不太選擇與我們合作的矯正醫師,也在說,你知道,這個產品其實真的有效。我不確定它是否適合我,但這東西確實真的有效。我對我所看到的感到驚訝。
Jeffrey Matthews - Analyst
Jeffrey Matthews - Analyst
Right.
對。
Tom Prescott - President, CEO
Tom Prescott - President, CEO
That has a huge positive halo effect for a GP that mostly worries about messing something up and losing a patient. So I think the -- and then the third thing is, we've had a lot of recommitment to more training and webinars. And our low-volume, medium- and high-volume customers, orthos and GPs, have -- are all very aware of the technology and they're becoming more comfortable that this is a very predictable product to use. It is still very technique sensitive, but I just think those things together are taking us to the right direction.
這對一位 GP 來說有非常大的正面光環效應,因為他們多半擔心把事情搞砸、失去病患。所以我認為——然後第三點是,我們重新投入了更多訓練與網路研討會。我們的低量能、中量能與高量能客戶——矯正醫師與 GP——都非常了解這項技術,也越來越放心,認為這是一個非常可預測、可使用的產品。它仍然非常吃技術手法,但我只是覺得這些因素加在一起,正把我們帶往正確的方向。
Jeffrey Matthews - Analyst
Jeffrey Matthews - Analyst
Great, thanks. And then it has been a year since the Cadent deal was announced, and two questions related to that. One is you identified some customer-facing issues at Cadent that cropped up as a result of the integration. Has Cadent been hurt by those, and what are you doing about it?
很好,謝謝。接著,Cadent 交易宣布至今已經一年了,有兩個相關問題。第一個是,你們指出 Cadent 因整合而浮現了一些面向客戶的問題。Cadent 是否因此受損?你們正在怎麼處理?
And then related to that, it has been a year since the deal, and if anything the move to digital seems to be more compelling now than it might have looked back then. What has surprised you about the deal positively or negatively?
另外也相關的是,交易至今已一年,而若有什麼不同,數位化的趨勢現在看起來比當時更具吸引力。這筆交易有哪些讓你驚訝的地方(正面或負面)?
Tom Prescott - President, CEO
Tom Prescott - President, CEO
Well, let me take the negative first, because we came to a logical -- first of all, we decided to fully integrate this business, not run it as a stand-alone business. It was too much like us and they did such terrific things and we had such complimentary skills.
好,我先談負面的,因為我們做了一個合乎邏輯的——首先,我們決定把這個業務完全整合,而不是把它當作獨立事業體來運作。它跟我們太像了;他們做得非常出色,而我們也有非常互補的能力。
We were kind of landlocked. We didn't have any more capacity to put milling and customer support and tech support in New Jersey. And given the opportunity, we decided to accelerate moving all of that to Juarez or to Costa Rica. We gave the employees there a year notice, and more in some cases and retention, and thought this is how we would talk to our own employees if we are going to make a change.
我們有點受限於場地。在新澤西,我們沒有更多產能來擴增研磨(milling)、客戶支援與技術支援。而在有這個機會的情況下,我們決定加速把這些全部移到華雷斯(Juarez)或哥斯大黎加。我們提前一年通知那裡的員工,有些情況甚至更早,並提供留任安排;我們認為,如果我們要做變更,這就是我們希望對自家員工溝通的方式。
And on the way we found is we were disconnecting some things that we hadn't quite rebuilt capabilities in the new place yet -- not everything was documented. And so I think in the areas of customer support and access to a skilled person to answer a question, and a few other things, we underperformed there.
而在過程中我們發現,我們正在切斷一些環節,但在新地點還沒有完全重建相應能力——並非所有事情都有文件化。因此在客戶支援、能否接觸到熟練人員來回答問題,以及其他幾個方面,我們表現不如預期。
And I am being -- just being brutally candid here that that is an opportunity for us to do better. We have tripled the number of resources there. We have got a great team in Costa Rica and Juarez. They are pulling that, and within a month or two I think we are going to be well past that -- moving past it.
我在這裡——坦白到近乎殘酷地說——這是我們可以做得更好的機會。我們已把那裡的資源人數增加到三倍。我們在哥斯大黎加與華雷斯都有很棒的團隊。他們正在把這件事拉起來,我想在一兩個月內,我們就會遠遠超過目前的狀況——把它翻過去。
So I think that is -- that was a little harder than we thought, and there were some pieces we didn't understand as well as we could have. In retrospect, if I had to play that back, we probably would have moved slower to make that happen. But, again, I think you do this a lot the risks of moving too slow are often greater of moving too fast. So we erred on the side of moving fast.
所以我認為那是——那確實比我們想像中更難一些,而且有些環節我們理解得不如本可以做到的程度。回頭看,如果要重來一次,我們可能會放慢腳步再推動那件事。但再說一次,我認為你做這種事很多時候,走得太慢的風險往往大於走得太快。所以我們選擇偏向快速推進。
On the positive side, there is so many that the amount -- the acceleration we have actually had in our technology and product side, the impact from our -- small efforts by our large sales team and marketing teams with great relationships, we have been far more effective at moving scanners and placing scanners in our -- in the Invisalign base. And I think at a strategic level we ere a little afraid that we were ahead of the party too much.
正面來說,有太多了:我們在技術與產品端實際取得的加速幅度、我們大型銷售團隊與行銷團隊憑藉良好關係所做的小幅努力所帶來的影響——我們在推動掃描器、並把掃描器部署到我們——Invisalign 客戶基礎中,成效遠比預期更好。而我認為在策略層面,我們曾有點擔心自己走得太前面、超前市場太多。
Our customers really get it. And I think as we start bringing on these tools that improve their workflow and make them more productive and delight the patient, that is going to just start -- those things will start to be multiplicative.
我們的客戶真的理解這件事。而我認為,當我們開始導入這些能改善他們工作流程、提升生產力並讓病患感到滿意的工具時,這將會開始——這些事情會開始產生乘數效應。
We are -- I think we are couple of months away from feeling the leverage for the Cadent customers. We will get through it. We are out talking to all of our lab customers and everybody else, but I'm being brutally honest here. We can do better here and we are. But the rest of it is just so positive. We are extremely excited about the long-term here.
我們——我想我們再過幾個月就會感受到對 Cadent 客戶的槓桿效益。我們會度過這段過程。我們正在與所有實驗室客戶以及其他所有人溝通,但我在這裡非常坦白。我們在這裡可以做得更好,而我們也正在改善。但其他方面都非常正面。我們對長期發展感到非常興奮。
Jeffrey Matthews - Analyst
Jeffrey Matthews - Analyst
Great. Terrific. Thanks again and good luck.
很好。太棒了。再次感謝,祝你們好運。
Shirley Stacy - VP, Corporate and Investor Communications
Shirley Stacy - VP, Corporate and Investor Communications
Well, thank you everyone for joining us today. This concludes our conference call. We look forward to seeing you at upcoming financial conferences and industry meetings. If you have any questions, please contact Investor Relations. Have a great day.
好的,感謝各位今天加入我們。本次電話會議到此結束。我們期待在接下來的財務研討會與產業會議上與各位見面。如有任何問題,請聯絡投資人關係部門。祝各位有美好的一天。
Operator
Operator
Ladies and gentlemen, this concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.
各位女士先生,今天的電話會議到此結束。您現在可以掛斷電話。感謝您的參與。